The present invention is directed to a compound, method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (hiv) and hepatitis B virus (hbv) infections, in human patients or other animal hosts, comprising the administration of N4-acylcytosine-1,3-dioxolane and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.
|
4. A compound selected from the group consisting of β-D-N4-p-iodobenzoyl-5-fluorocytidine-1,3-dioxolane, β-D-N4-p-fluoro-benzoyl-5-fluorocytidine-1,3-dioxolane, β-D-N4-p-chlorobenzoyl-5-fluoro-cytidine-1,3-dioxolane, β-D-N4-p-bromobenzoyl-5-fluorocytidine-1,3-dioxolane, β-D-N4-p-ethyl-benzoyl-5-fluorocytidine-1,3-dioxolane, and β-D-N4-p-t-butylbenzoyl-5-fluoro-cytidine-1,3-dioxolane.
23. A pharmaceutical composition that includes an effective hiv or hbv treatment amount of a compound selected from the group consisting of β-D-N4-p-iodobenzoyl-5-fluorocytidine-1,3-dioxolane, β-D-N4-p-fluoro-benzoyl-5-fluorocytidine-1,3-dioxolane, β-D-N4-p-chlorobenzoyl-5-fluoro-cytidine-1,3-dioxolane, β-D-N4-p-bromobenzoyl-5-fluorocytidine-1,3-dioxolane, β-D-N4-p-ethyl-benzoyl-5-fluorocytidine-1,3-dioxolane, and β-D-N4-p-t-butylbenzoyl-5-fluoro-cytidine-1,3-dioxolane.
30. A method for the treatment of a host infected with hiv that includes administering an effective amount of a compound selected from the group consisting of β-D-N4-p-iodobenzoyl-5-fluorocytidine-1,3-dioxolane, β-D-N4-p-fluoro-benzoyl-5-fluorocytidine-1,3-dioxolane, β-D-N4-p-chlorobenzoyl-5-fluoro-cytidine-1,3-dioxolane, β-D-N4-p-bromobenzoyl-5-fluorocytidine-1,3-dioxolane, β-D-N4-p-ethyl-benzoyl-5-fluorocytidine-1,3-dioxolane, and β-D-N4-p-t-butylbenzoyl-5-fluoro-cytidine-1,3-dioxolane.
0. 37. A compound of the formula:
##STR00062##
or a pharmaceutically acceptable salt thereof, wherein
i) R1 is hydrogen;
ii) R2 is chosen from alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, heteroaryl, and C6H4R6 where R6 is chosen from halogen, CN, CF3, N3, NO2, alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, and aryl;
iii) R3 is chosen from halogen, CN, CF3, N3, NO2, alkyl, alkenyl, and alkynyl;
iv) R3′ is chosen from H, halogen, methyl, or ethyl; and
v) R4 is chosen from H, phosphate, carbonyl substituted with alkyl, alkenyl, alkynyl, aryl, sulfonate ester, a lipid, an amino acid, a peptide, or cholesterol.
or a pharmaceutically acceptable salt thereof, wherein
i) R1 is chosen from hydrogen and halogen;
ii) R2 is chosen from alkyl, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, heteroaryl, and C6H4R6 where R6 is chosen from halogen, CN, CF3, N3, NO2, alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, and aryl;
iii) R3 is chosen from halogen, CN, CF3, N3, NO2, alkyl, alkenyl, and alkynyl;
iv) R3′ is chosen from H, halogen, methyl, or ethyl; and
v) R4 is chosen from H, phosphate, carbonyl substituted with alkyl, alkenyl, alkynyl, aryl, sulfonate ester, a lipid, an amino acid, a peptide, or cholesterol.
0. 35. A method for the treatment of a host infected with hbv that comprises administering an effective amount of a compound of the formula:
##STR00060##
or a pharmaceutically acceptable salt thereof, wherein
i) R1 is hydrogen;
ii) R2 is chosen from alkyl, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, heteroaryl, and C6H4R6 where R6 is chosen from halogen, CN, CF3, N3, NO2, alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, and aryl;
iii) R3 is chosen from halogen, CN, CF3, N3, NO2, alkyl, alkenyl, and alkynyl;
iv) R3′ is chosen from H, halogen, methyl, or ethyl; and
v) R4 is chosen from H, phosphate, carbonyl substituted with alkyl, alkenyl, alkynyl, aryl, sulfonate ester, a lipid, an amino acid, a peptide, or cholesterol.
25. A method for the treatment of a host infected with hbv that includes administering an effective amount of a compound of the formula:
##STR00057##
or a pharmaceutically acceptable salt thereof, wherein
ix) R1 is chosen from hydrogen and halogen;
x) R2 is chosen from alkyl, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, heteroaryl, and C6H4R6 where R6 is chosen from halogen, CN, CF3, N3, NO2, alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, and aryl;
xi) R3 is chosen from H, halogen, CN, CF3, N3, NO2, alkyl, alkenyl, and alkynyl;
xii) R3′ is chosen from H, halogen, methyl, or ethyl; and
xiii) R4 is H, phosphate, carbonyl substituted with alkyl, alkenyl, alkynyl, aryl, sulfonate ester, a lipid, an amino acid, a peptide, or cholesterol,
in a pharmaceutically acceptable carrier.
24. A method for the treatment of a host infected with hiv that includes administering an effective amount of a compound of the formula:
##STR00056##
or a pharmaceutically acceptable salt thereof, wherein
iv) R1 is chosen from hydrogen and halogen;
v) R2 is chosen from alkyl, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, heteroaryl, and C6H4R6 where R6 is chosen from halogen, CN, CF3, N3, NO2, alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, and aryl;
vi) R3 is chosen from H, halogen, CN, CF3, N3, NO2, alkyl, alkenyl, and alkynyl;
vii) R3′ is chosen from H, halogen, methyl, or ethyl; and
viii) R4 is H, phosphate, carbonyl substituted with alkyl, alkenyl, alkynyl, aryl, sulfonate ester, a lipid, an amino acid, a peptide, or cholesterol,
in a pharmaceutically acceptable carrier.
26. A method for the treatment of a host infected with hiv that includes administering an effective amount of a compound of the formula:
##STR00058##
or a pharmaceutically acceptable salt thereof, wherein
xiv) R1 is chosen from hydrogen and halogen;
xv) R2 is chosen from alkyl, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, heteroaryl, and C6H4R6 where R6 is chosen from halogen, CN, CF3, N3, NO2, alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, and aryl;
xvi) R3 is chosen from H, halogen, CN, CF3, N3, NO2, alkyl, alkenyl, and alkynyl;
xvii) R3′ is chosen from H, halogen, methyl, or ethyl; and
xviii) R4 is H, phosphate, carbonyl substituted with alkyl, alkenyl, alkynyl, aryl, sulfonate ester, a lipid, an amino acid, a peptide, or cholesterol,
in a pharmaceutically acceptable carrier in combination with another anti-hiv agent.
27. A method for the treatment of a host infected with hbv that includes administering an effective amount of a compound of the formula:
##STR00059##
or a pharmaceutically acceptable salt thereof, wherein
xix) R1 is chosen from hydrogen and halogen;
xx) R2 is chosen from alkyl, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, heteroaryl, and C6H4R6 where R6 is chosen from halogen, CN, CF3, N3, NO2, alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, and aryl;
xxi) R3 is chosen from H, halogen, CN, CF3, N3, NO2, alkyl, alkenyl, and alkynyl;
xxii) R3′ is chosen from H, halogen, methyl, or ethyl; and
xxiii) R4 is H, phosphate, carbonyl substituted with alkyl, alkenyl, alkynyl, aryl, sulfonate ester, a lipid, an amino acid, a peptide, or cholesterol,
in a pharmaceutically acceptable carrier in combination with another anti-hiv anti-hbv agent.
0. 36. A method for the treatment of a host infected with hbv that comprises administering an effective amount of a compound in a pharmaceutically acceptable carrier in combination with another anti-hbv agent, wherein the compound has the formula:
##STR00061##
or a pharmaceutically acceptable salt thereof, wherein
i) R1 is hydrogen;
ii) R2 is chosen from alkyl, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, heteroaryl, and C6H4R6 where R6 is chosen from halogen, CN, CF3, N3, NO2, alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, and aryl;
iii) R3 is chosen from halogen, CN, CF3, N3, NO2, alkyl, alkenyl, and alkynyl;
iv) R3′ is chosen from H, halogen, methyl, or ethyl; and
v) R4 is chosen from H, phosphate, carbonyl substituted with alkyl, alkenyl, alkynyl, aryl, sulfonate ester, a lipid, an amino acid, a peptide, or cholesterol.
5. A compound selected from the following, or its pharmaceutically acceptable salt:
β-D-5-fluoro-N4-(4-iodobenzoyl)cytidine-1,3-dioxolane of the structure:
##STR00024##
β-D-5-fluoro-N4-(4-fluorobenzoyl)cytidine-1,3-dioxolane of the structure:
##STR00025##
β-D-N4-(4-chlorobenzoyl)-5-fluorocytidine-1,3-dioxolane of the structure:
##STR00026##
β-D-N4-(4-bromobenzoyl)-5-fluorocytidine-1,3-dioxolane of the structure:
##STR00027##
β-D-5-fluoro-N4-(3-fluorobenzoyl)cytidine-1,3-dioxolane of the structure:
##STR00028##
β-D-N4-(3-chlorobenzoyl)-5-fluorocytidine-1,3-dioxolane of the structure:
##STR00029##
β-D-N4-(3-bromobenzoyl)-5-fluorocytidine-1,3-dioxolane of the structure:
##STR00030##
β-D-5-fluoro-N4-(4-nitrobenzoyl)cytidine-1,3-dioxolane of the structure:
##STR00031##
β-D-5-fluoro-N4-p-toluoylcytidine-1,3-dioxolane of the structure:
##STR00032##
β-D-5-fluoro-N4-(m-toluoyl)cylidine-1,3-dioxolane of the structure:
##STR00033##
β-D-N4-(4-ethylbenzoyl)-5-fluorocytidine-1,3-dioxolane of the structure:
##STR00034##
β-D-5-fluoro-N4-(4-propylbenzoyl)cytidine-1,3-dioxolane of the structure:
##STR00035##
β-D-N4-(4-tert-butylbenzoyl)-5-fluorocytidine-1,3-dioxolane of the structure:
##STR00036##
β-D-5-fluoro-N4-(2-thiophenecarbonyl)cytidine-1,3-dioxolane of the structure:
##STR00037##
β-D-N4-(benzo-[b]-thiophene-2-carbonyl)-5-fluorocytidine-1,3-dioxolane of the structure:
##STR00038##
and β-D-N4-(cyclohexane-carbonyl)-5-fluorocytidine-1,3-dioxolane of the structure:
##STR00039##
6. The compound of
7. The compound of
β-D-5-fluoro-N4-(4-fluorobenzoyl)cytidine-1,3-dioxolane of the structure:
##STR00041##
8. The compound of
β-D-N4-(4-chlorobenzoyl)-5-fluorocytidine-1,3-dioxolane of the structure:
##STR00042##
9. The compound of
β-D-N4-(4-bromobenzoyl)-5-fluorocytidine-1,3-dioxolane of the structure:
##STR00043##
10. The compound of
β-D-5-fluoro-N4-(3-fluorobenzoyl)cytidine-1,3-dioxolane of the structure:
##STR00044##
11. The compound of
β-D-N4-(3-chlorobenzoyl)-5-fluorocytidine-1,3-dioxolane of the structure:
##STR00045##
12. The compound of
β-D-N4-(3-bromobenzoyl)-5-fluorocytidine-1,3-dioxolane of the structure:
##STR00046##
13. The compound of
β-D-5-fluoro-N4-(4-nitrobenzoyl)cytidine-1,3-dioxolane of the structure:
##STR00047##
14. The compound of
β-D-5-fluoro-N4-p-toluoylcytidine-1,3-dioxolane of the structure:
##STR00048##
15. The compound of
β-D-5-fluoro-N4-(m-toluoyl)cytidine-1,3-dioxolane of the structure:
##STR00049##
16. The compound of
β-D-N4-(4-ethylbenzoyl)-5-fluorocytidine-1,3-dioxolane of the structure:
##STR00050##
17. The compound of
β-D-5-fluoro-N4-(4-propylbenzoyl)cytidine-1,3-dioxolane of the structure:
##STR00051##
18. The compound of
β-D-N4-(4-tert-butylbenzoyl)-5-fluorocytidine-1,3-dioxolane of the structure:
##STR00052##
19. The compound of
β-D-N4-(cyclohexane-carbonyl)-5-fluorocytidine-1,3-dioxolane of the structure:
##STR00053##
20. The compound of
β-D-5-fluoro-N4-(2-thiophenecarbonyl)cytidine-1,3-dioxolane of the structure:
##STR00054##
21. The compound of
β-D-N4-(benzo-[b]-thiophene-2-carbonyl)-5-fluorocytidine-1,3-dioxolane of the structure:
##STR00055##
22. A pharmaceutical composition that includes an effective hiv or hbv treatment amount of a compound of
28. The method of claims 24, 25, 26 or 27 wherein R1 is fluorine.
29. The method of claims 24, 25, 26, or 27 wherein R3 is fluorine and R3′ is H.
31. A method for the treatment of a host infected with hbv that includes administering an effective amount of a compound of one of
32. A method for the treatment of a host infected with hiv that includes administering an effective amount of a compound of one of
33. A method for the treatment of a host infected with hiv that includes administering an effective amount of a compound of one of
34. A method for the treatment of a host infected with hbv that includes comprises administrating an effective amount of a compound of one of
0. 38. The compound of
0. 39. A pharmaceutical composition that comprises an effective hiv or hbv treatment amount of a compound of
0. 40. A method for the treatment of a host infected with hiv that comprises administering an effective amount of a compound of
0. 41. A method for the treatment of a host infected with hbv that comprises administering an effective amount of a compound of
0. 42. A method for the treatment of a host infected with hiv that comprises administering an effective amount of a compound of
0. 43. A method for the treatment of a host infected with hbv that comprises administering an effective amount of a compound of
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The present application claims priority to U.S. Ser. No. 60/341,555 filed on Dec. 14, 2001.
The present invention is directed to compounds, methods and compositions for the treatment or prevention of viral infections using nucleoside analogues. More specifically, the invention describes N4-acyl-substituted cytosine nucleoside analogues, pharmaceutically acceptable salts, prodrugs, or other derivatives thereof, and the use thereof in the treatment of a viral infection, and in particular a human immunodeficiency virus (HIV) or hepatitis B virus (HBV) infection.
In 1981, acquired immune deficiency syndrome (AIDS) was identified as a disease that severely compromises the human immune system, and that without exception leads to death. In 1983, the etiological cause of AIDS was determined to be what is now known as human immunodeficiency virus (HIV).
Another virus that causes a serious human health problem is the hepatitis B virus (HBV). HBV is second only to tobacco as a cause of human cancer. The mechanism by which HBV induces cancer is unknown. It is postulated that it may directly trigger tumor development, or indirectly trigger tumor development through chronic inflammation, cirrhosis, and cell regeneration associated with the infection.
After a 2- to 6-month incubation period, during which the host is typically unaware of the infection, HBV infection can lead to acute hepatitis and liver damage, resulting in abdominal pain, jaundice and elevated blood levels of certain enzymes. HBV can cause fulminant hepatitis, a rapidly progressive, often fatal form of the disease in which large sections of the liver are destroyed.
Patients typically recover from the acute phase of HBV infection. In some patients, however, high levels of viral antigen persist in the blood for an extended, or indefinite, period, causing a chronic infection. Chronic infections can lead to chronic persistent hepatitis. Patients infected with chronic persistent HBV are most common in developing countries. By mid-1991, there were approximately 225 million chronic carriers of HBV in Asia alone, and worldwide, almost 300 million carriers. Chronic persistent hepatitis can cause fatigue, cirrhosis of the liver, and hepatocellular carcinoma, a primary liver cancer.
In Western, industrialized countries, the high-risk group for HBV infection includes those in contact with HBV carriers or their blood samples. The epidemiology of HBV is very similar to that of HIV/AIDS, which is a reason why HBV infection is common among patients infected with HIV or suffering from AIDS. However, HBV is more contagious than HIV.
In 1985, it was reported that the synthetic nucleoside 3′-azido-3′-deoxythymidine (AZT) inhibited the replication of HIV. Since then, several other synthetic nucleosides, including but not limited to 2′,3′-dideoxyinosine (ddI), 2′,3′-dideoxycytidine (ddC), 2′,3′-dideoxy-2′,3′-didehydrothymidine (d4T), (−)-2′,3′-dideoxy-3′-thiacytidine (3TC), and (−)-carbocyclic 2′,3′-didehydro-2′,3′-dideoxyguanosine (carbovir) and its prodrug abacavir, have proven effective against HIV. After phosphorylation to the 5′-triphosphate by cellular kinases, these synthetic nucleosides are incorporated into a growing strand of viral DNA, causing chain termination, because they lack a 3′-hydroxyl group. Some nucleosides also inhibit the viral enzyme reverse transcriptase.
3TC (lamivudine) and interferon are currently the only FDA-approved drugs for the treatment of HBV infection. Viral resistance develops within 6 months of 3TC treatment in about 14% of patients.
Cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (FTC) is currently in clinical trials for the treatment of HIV and separately for HBV by Triangle Pharmaceuticals, Inc. See Schinazi et al. (1992) Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolane-5-yl]cytosine. Antimicrob. Agents Chemother. 36, 2423-2431; U.S. Pat. Nos. 5,210,085; 5,914,331; 5,814,639; WO 91/11186; and WO 92/14743.
There has also been a signficant amount of research on 1,3-dioxolane nucleosides and their use to treat viral infections. U.S. Pat. Nos. 5,210,085; 5,276,151; 5,852,027; and 5,179,104 disclose 5-fluorocytosine-1,3-dioxolane nucleoside and nucleoside analogues for the treatment of viral infections.
The success of various synthetic nucleosides in inhibiting the replication of HIV in vivo or in vitro has led a number of researchers to design and test nucleosides that substitute a heteroatom for the carbon atom at the 3′-position of the nucleoside. Norbeck, et al., disclosed that (+/−)-1-[(2-β,4-β)-2-(hydroxymethyl)-4-dioxolanyl]thymine (referred to as (+/−)-dioxolane-T) exhibits a modest activity against HIV (EC50 of 20 μM in ATH8 cells), and is not toxic to uninfected control cells at a concentration of 200 μM. Tetrahedron Letters 30 (46), 6246, (1989).
On Apr. 11, 1988, Bernard Belleau, Dilip Dixit, and Nghe Nguyen-Ba at BioChem Pharma filed patent application U.S. Ser. No. 07/179,615 which disclosed a generic group of racemic 2-substituted-4-substituted-1,3-dioxolane nucleosides for the treatment of HIV. The '615 patent application matured into European Patent Publication No. 0 337 713; U.S. Pat. No. 5,041,449; and U.S. Pat. No. 5,270,315 assigned to BioChem Pharma, Inc.
On Dec. 5, 1990, Chung K. Chu and Raymond F. Schinazi filed U.S. Ser. No. 07/622,762, which disclosed an asymmetric process for the preparation of enantiomerically pure β-D-1,3-dioxolane nucleosides via stereospecific synthesis, and certain nucleosides prepared thereby, including (−)-(2R,4R)-9-[(2-hydroxymethyl)-1,3-dioxolan-4-yl]guanine (DXG), and its use to treat HIV. This patent application issued as U.S. Pat. No. 5,179,104. ##STR00001##
On May 21, 1991, Tarek Mansour, et al., at BioChem Pharma filed U.S. Ser. No. 07/703,379 directed to a method to obtain the enantiomers of 1,3-dioxolane nucleosides using a stereoselective synthesis that includes condensing a 1,3-dioxolane intermediate covalently bound to a chiral auxiliary with a silyl Lewis acid. The corresponding application filed in Europe was EP 0 515 156.
On Aug. 25, 1992, Chung K. Chu and Raymond F. Schinazi filed U.S. Ser. No. 07/935,515, disclosed certain enantiomerically pure β-D-dioxolanyl purine compounds for the treatment of humans infected with HIV of the formula:
##STR00002##
wherein R is OH, Cl, NH2, or H, or a pharmaceutically acceptable salt or derivative of the compounds optionally in a pharmaceutically acceptable carrier or diluent. The compound wherein R is chloro is referred to as (−)-(2R,4R)-2-amino-6-chloro-9-[(2-hydroxymethyl)-1,3-dioxolan-4-yl]purine. The compound wherein R is hydroxy is (−)-(2R,4R)-9-[(2-hydroxy-methyl)-1,3-dioxolan-4-yl]guanine. The compound wherein R is amino is (−)-(2R,4R)-2-amino-9-[(2-hydroxymethyl)-1,3-dioxolan-4-yl]adenine. The compound wherein R is hydrogen is (−)-(2R,4R)-2-amino-9-[(2-hydroxymethyl)-1,3-dioxolan-4yl]purine. This application issued as U.S. Pat. No. 5,925,643.
In 1992, Kim et al., published an asymmetric synthesis for selected 1,3-dioxolane pyrimidine nucleosides from 1,6-anhydro-D-mannose. The specific synthesis resulted in β-D and α-D enantiomers of 1,3-dioxolane nucleosides. Kim et al., 1,3-Dioxolanylpurine Nucleosides (2R,4R) and (2R,4S) with Selective Anti-HIV-1 Activity in Human Lymphocytes, J. Med. Chem., 1993 36, 30-37.
In 1992, Belleau et al., at BioChem Pharma, published a method to obtain enantiomerically pure 1,3-dioxolane nucleosides via L-ascorbic acid as a chiral auxiliary in the process. L-ascorbic acid was used to produce a set of diastereomers which could be separated. Belleau, et al., Oxidative Degradation of L-Ascorbic Acid Acetals to 2′,3′-Dideoxy-3′-Oxaribofuranosides Synthesis of Enantiomerically Pure 2′,3′-Dideoxy-3′-Oxaribofuranosides. Synthesis of Enantiomerically Pure 2′,3′-Dideoxy-3′-Oxacytidine Stereoisomers as Potential Antiviral Agents. Tetrahedron Lett. 1992, 33:6949.
On Feb. 21, 1992, PCT/US92/01393 (WO 92/14729) by Liotta et al. disclosed a method for the synthesis of 1,3-dioxolane nucleosides that includes condensing a 2-O-protected-5-O-acylated-1,3-dioxolane with a purine of pyrimidine base in the presence of a titanium containing Lewis acid to provide predominately the desired O-isomer in the C1′-position of a 1,3-dioxolane nucleoside. WO 92/14729 also disclosed a process for the resolution of a racemic mixture of 1,3-dioxolane nucleoside enantiomers.
In 1992, Kim et al., published an article teaching how to obtain (−)-L-β-dioxolane-C and (+)-L-β-dioxolane-T from 1,6-anhydro-L-β-glucopyranose. Kim et al., Potent anti-HIV and anti-HBV Activities of (−)-L-β-Dioxolane-C and (+)-L-β-Dioxolane-T and Their Asymmetric Syntheses, Tetrahedron Letters Vol 32(46), pp 5899-6902.
On Oct. 28, 1992, Raymond Schinazi filed U.S. Ser. No. 07/967,460 directed to the use of the compounds disclosed in U.S. Ser. No. 07/935,515 for the treatment of hepatitis B. This application has issued as U.S. Pat. Nos. 5,444,063; 5,684,010; 5,834,474; and 5,830,898.
In 1993, Jin et al., at BioChem Pharma published an article that concluded that Lewis acids play a crucial role in the preparation 1,3-dioxolane nucleosides. TiC4 and SnCl4 promote the formation of dioxolane nucleosides with racemization in the coupling of enantiomerically pure 2′-deoxy-3′-oxaribosides with silylated N-acetylcytosine. The use of the Lewis acids trimethylsilyltriflate, trimethylsilyl iodide, and TiCl2(O-iPr)2 furnished enantiomerically pure cytosine dioxolane nucleosides in low diastereoselectivity. Unexpected Effects of Lewis Acids in the Synthesis of Optically Pure 2′-Deoxy-3′-Oxacytidine Nucleoside Analogs, Tetrahedron Asymmetry vol 4, No. 2 pp 211-214 (1993).
In 1993, Siddiqui, et al., at BioChem and Glaxo published that cis-2,6-diaminopurine dioxolane can be deaminated selectively using adenosine deaminase. Siddiqui, et al., Antiviral Optically Pure dioxolane Purine Nucleoside Analogues, Bioorganic & Medicinal Chemistry Letters, Vol. 3 (8), pp 1543-1546 (1993). (−)-(2R,4R)-2-amino-9-[(2-hydroxymethyl)-1,3-dioxolan-4-yl]adenine (DAPD) is a selective inhibitor of HIV-1 replication in vitro as a reverse transcriptase inhibitor (RTI). DAPD is thought to be deaminated in vivo by adenosine deaminase, a ubiquitous enzyme, to yield (−)-β-D-dioxolane guanine (DXG), which is subsequently converted to the corresponding 5′-tri-phosphate (DXG-TP). Biochemical analysis has demonstrated that DXG-TP is a potent inhibitor of the HIV reverse transcriptase (HIV-RT) with a Ki of 0.019 μM. ##STR00003##
Other nucleosides that have been successful in anti-viral treatments include of 2′,3′-dideoxy- and 2′,3′-didehydro-2,3′-dideoxy-nucleosides (referred to as a “ddN” or “d2N” nucleoside and a “d4N” nucleoside, respectively), particularly, these nucleosides inhibit the replication of HIV in vivo or in vitro, thus, has led a number of researchers to design and test a variety of modified d2- and d4-nucleosides. One modification has been the replacement of the 5-hydrogen on cytosine nucleosides with fluorine, resulting in several 5-fluorocytosine nucleosides with antiviral activity, including but not limited to β-D- and β-L-2′,3′-dideoxy-5-fluorocytine (β-D-D2FC and β-L-D2FC) (U.S. Pat. Nos. 4,788,181 and 6,156,737).
β-D-2′,3′-Dideoxy-2′,3′-didehydro-5-fluorocytidine (d4FC) and its use to treat hepatitis B was first described in Example 2 of European Pat. Application No. 0 409 227 A2 (Ajinomoto Co., Inc.). Netherlands Pat. No. 8901258 (Stichting Rega V. Z. W.) discloses generally 5-halogeno-2′,3′-dideoxy-2′,3′-didehydrocytidine derivatives for use in treating HIV and HBV. β-D- and β-L-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine were further described in U.S. Pat. Nos. 5,703,058; 5.905,070; 6,232,300; and 5,561,120. U.S. Pat. No. 5,703,058 claims a method for the treatment of HIV and/or HBV infection that includes administering an effective amount of β-L-d4FC in combination or alternation with cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane, cis-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane, 9-[4-(hydroxymethyl)-2-cyclopenten-1-yl)-guanine (carbovir), 9-[(2-hydroxyethoxy)methyl]-guanine (acyclovir), interferon, 3′-deoxy-3′-azido-thymidine (AZT), 2′,3′-dideoxyinosine (ddI), 2′,3′-dideoxycytidine (ddC), (−)-2′-fluoro-5-methyl-β-L-ara-uridine (L-FMAU) or 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T). U.S. Pat. No. 5,905,070 claims a method for the treatment of HIV and HBV infection that includes administering an effective amount of β-D-d4FC in combination or alternation with cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane, cis-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane, 9-[4-(hydroxy-methyl)-2-cyclopenten-1-yl)-guanine (carbovir), 9-[(2-hydroxyethoxy)methyl]guanine (acyclovir), interferon, 3′-deoxy-3′-azido-thymidine (AZT), 2′,3′-dideoxyinosine (ddI), 2′,3′-dideoxycytidine (ddC), (−)-2′-fluoro-5-methyl-β-L-ara-uridine (L-FMAU) or 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T). U.S. Pat. No. 6,232,300 claims a method to treat HIV with β-D-d4FC.
Modification of the amino group of antiviral cytosine nucleosides has not been fully explored. Only a few N4-substituted cytosine 2′,3′-dideoxy nucleosides and N4-substituted cytosine 2′,3′-didehydro-2′,3′-dideoxy nucleosides have been reported. These include N4-benzoyl-2′,3′-didehydro-2,′3-dideoxycytidine (Kawaguchi et al., Studies on 2′,3′-dideoxy-2′,3′-didehydropyrimidine nucleosides. II. N4-benzoyl-2′,3′-dideoxy-2′,3′-didehydrocytidine as a prodrug of 2′,3′-dideoxy-2′,3′-didehydrocytidine (DDCN), Chem. Pharm. Bull. (1989), 37(9), 2547-9), N4-benzoyl-2′,3′-dideoxycytidine (Gulbis et al. (1993) Structure of a dideoxynucleoside active against the HIV (AIDS) virus. Acta Cryst. C49, 1095-1097), N4-acetyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine, and N4-isopropyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine (Shi et al. (1999)) Synthesis and biological evaluation of 2′,3′-didehydro-2′,3′-aideoxy-5-fluorocytidine (d4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase. J. Med. Chem. 42, 859-867). Of the sugar-modified cytosine nucleosides, some N4-acyl and imine-substituted 2′,3′-dideoxy-3′-C-hydroxymethylcytidine analogues have been synthesized (Mauldin et al. (1998) Synthesis and antiviral activity of prodrugs of the nucleoside 1-[2′,3′-dideoxy-3′-C-(hydroxymethyl)-β-D-erythropentofuranosyl] cytosine. Bioorg. Med. Chem. 6, 577-585), and some N4-acetyl- and phosphonoacetyl-2′,3′-dideoxy-3′-thiacytidine nucleosides have been prepared (Charvet et al. (1993) Inhibition of human immunodeficiency virus type 1 replication by phosphonoformate- and phosphonoacetate-2′,3′-dideoxy-3′-thiacytidine conjugates. J. Med. Chem. 37, 2216-2223).
Therefore, it is an object of the present invention to provide a compound, method and composition for the treatment or prevention of HIV infection in human patients.
It is another object of the present invention to provide a compound, method and composition for the treatment or prevention of HBV infection in human patients or other host animals.
It is still another object of the present invention to provide a compound, method and composition for the treatment or prevention of HIV and HBV infection in human patients or other host animals.
It has been found that certain N4-acyl-cytosine 1,3-dioxolane nucleosides, and in particular, N4-acyl-5-fluorocytidine-1,3-dioxolane, show improved inhibitory activity against HIV and HBV. Therefore, a method for the treatment or prevention of HIV and/or HBV infection in a host, and in particular, a human, is provided that includes administering an effective amount of a N4-acyl-cytosine nucleoside.
In one embodiment of the present invention, the active compound is of formula (A):
##STR00004##
wherein R1 is chosen from hydrogen, halogen (F, Cl, Br, I), alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl, CN, CF3, N3, NO2, aryl, heteroaryl and acyl;
The compound of the present invention can be in the form of the isolated β-L- or β-D-configuration, or a mixture thereof, including but not limited to a racemic mixture.
In addition, the N4-acylcytosine-1,3-dioxolane nucleosides are inhibitors of HBV. Therefore, these compounds can also be used to treat patients that are co-infected with both HIV and HBV.
The present invention provides a compound, method and composition for treating an HIV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
The present invention provides a compound, method and composition for preventing an HIV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
The present invention provides a compound, method and composition for treating an HBV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
The present invention provides a compound, method and composition for preventing an HBV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
The present invention provides a use of a compound for the treatment of HIV and/or HBV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
The present invention provides a method of manufacture for a therapeutically effective compound for the treatment of an HIV and/or HBV infection.
In another aspect, there is provided a pharmaceutical formulation comprising a compound of the invention in combination with a pharmaceutically acceptable carrier or excipient for the treatment of a host infected with HIV or HBV.
In still another aspect, there is provided a compound, method and composition for treating or preventing an HIV infection in a host comprising administering to the subject a combination comprising at least one compound of the invention and at least one further therapeutic agent.
In still another aspect, there is provided a method and composition for treating or preventing an HBV infection in a host comprising administering to the subject a combination comprising at least one compound of the invention and at least one further therapeutic agent.
It has been found that N4-acyl-cytosine-1,3-dixolane nucleosides, and in particular, N4-acyl-5-fluorocytidine-1,3-dioxolane, show improved inhibitory activity against HIV and HBV. Therefore, a method for the treatment or prevention of a host, and in particular, a human, infected with HIV and/or HBV, is provided that includes administering an effective amount of an N4-acyl-cytosine-1,3-dioxolane nucleosides.
The present invention also provides a compouind, method and composition for treating an HIV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
The present invention provides a compound, method and composition for preventing an HIV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
The present invention provides a compound, method and composition for treating an HBV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
The present invention provides a compound, method and composition for preventing an HBV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
In another aspect, there is provided a pharmaceutical formulation comprising a compound of the invention in combination with a pharmaceutically acceptable carrier or excipient.
In still another aspect, there is provided a method and composition for treating or preventing an HIV infection in a host comprising administering to the subject a combination comprising at least one compound of the invention and at least one further therapeutic agent.
In still another aspect, there is provided a method and composition for treating or preventing an HBV infection in a host comprising administering to the subject a combination comprising at least one compound of the invention and at least one further therapeutic agent.
I. Active Compound
In one embodiment of the present invention, the active compound is of formula (A):
##STR00005##
wherein R1 is chosen from hydrogen, halogen (F, Cl, Br, I), alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl, CN, CF3, N3, NO2, aryl, heteroaryl and acyl;
The compound of the present invention can be in the form of the isolated β-L- or β-D-configuration, or a mixture thereof, including but not limited to a racemic mixture.
In one embodiment of the present invention, the active compound is β-D-N4-p-iodobenzoyl-5-fluorocytidine-1,3-dioxolane, β-D-N4-p-fluoro-benzoyl-5-fluorocytidine-1,3-dioxolane, β-D-N4-p-chlorobenzoyl-5-fluoro-cytidine-1,3-dioxolane, β-D-N4-p-bromobenzoyl-5-fluorocytidine-1,3-dioxolane, β-D-N4-p-ethyl-benzoyl-5-fluorocytidine-1,3-dioxolane, and β-D-N4-p-t-butylbenzoyl-5-fluoro-cytidine-1,3-dioxolane.
In one embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In one embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula, its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A); its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In one embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In yet another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
In another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In another embodiment of the present invention, the active compound is of formula (A), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
In one preferred embodiment, the active compound is β-D-5-fluoro-N4-(4-iodobenzoyl)cytidine-1,3-dioxolane of the structure:
##STR00006##
or a pharmaceutically acceptable salt or prodrug thereof.
In another preferred embodiment, the active compound is β-D-5-fluoro-N4-(4-fluorobenzoyl)cytidine-1,3-dioxolaneof the structure:
##STR00007##
or a pharmaceutically acceptable salt or prodrug thereof.
In still another preferred embodiment, the active compound is β-D-N4-(4-chlorobenzoyl)-5-fluorocytidine-1,3-dioxolane of the structure:
##STR00008##
or a pharmaceutically acceptable salt or prodrug thereof.
In one preferred embodiment, the active compound is β-D-N4-(4-bromobenzoyl)-5-fluorocytidine-1,3-dioxolane of the structure:
##STR00009##
or a pharmaceutically acceptable salt or prodrug thereof.
In another preferred embodiment, the active compound is β-D-5-fluoro-N4-(3-fluorobenzoyl)cytidine-1,3-dioxolane of the structure:
##STR00010##
or a pharmaceutically acceptable salt or prodrug thereof.
In still another preferred embodiment, the active compound is β-D-N4-(3-chlorobenzoyl)-5-fluorocytidine-1,3-dioxolane of the structure:
##STR00011##
or a pharmaceutically acceptable salt or prodrug thereof.
In one preferred embodiment, the active compound is β-D-N4-(3-bromobenzoyl)-5-fluorocytidine-1,3-dioxolane of the structure:
##STR00012##
or a pharmaceutically acceptable salt or prodrug thereof.
In another preferred embodiment, the active compound is β-D-5-fluoro-N4-(4-nitrobenzoyl)cytidine-1,3-dioxolane of the structure:
##STR00013##
or a pharmaceutically acceptable salt or prodrug thereof.
In still another preferred embodiment, the active compound is β-D-5-fluoro-N4-p-toluoylcytidine-1,3-dioxolane of the structure:
##STR00014##
or a pharmaceutically acceptable salt or prodrug thereof.
In one preferred embodiment, the active compound is β-D-5-fluoro-N4-(m-toluoyl)cytidine-1,3-dioxolane of the structure:
##STR00015##
or a pharmaceutically acceptable salt or prodrug thereof.
In another preferred embodiment, the active compound is β-D-N4-(4-ethylbenzoyl)-5-fluorocytidine-1,3-dioxolane of the structure:
##STR00016##
or a pharmaceutically acceptable salt or prodrug thereof.
In still another preferred embodiment, the active compound is β-D-5-fluoro-N4-(4-propylbenzoyl)cytidine-1,3-dioxolane of the structure:
##STR00017##
or a pharmaceutically acceptable salt or prodrug thereof.
In one preferred embodiment, the active compound is β-D-N4-(4-tert-butylbenzoyl)-5-fluorocytidine-1,3-dioxolane of the structure:
##STR00018##
or a pharmaceutically acceptable salt or prodrug thereof.
In still another preferred embodiment, the active compound is β-D-5-fluoro-N4-(2-thiophenecarbonyl)cytidine-1,3-dioxolane of the structure:
##STR00019##
or a pharmaceutically acceptable salt or prodrug thereof.
In one preferred embodiment, the active compound is β-D-N4-(benzo-[b]-thiophene-2-carbonyl)-5-fluorocytidine-1,3-dioxolane of the structure:
##STR00020##
or a pharmaceutically acceptable salt or prodrug thereof.
In another preferred embodiment, the active compound is β-D-N4-(cyclohexane-carbonyl)-5-fluorocytidine-1,3-dioxolane of the structure:
##STR00021##
or a pharmaceutically acceptable salt or prodrug thereof.
II. Stereoisomerism and Polymorphism
The compounds of the present invention have asymmetric centers and occur as racemates, racemic mixtures, individual diastereomers or enantiomers, with all isomeric forms being included in the present invention. Some compounds may exhibit polymorphism. The present invention encompasses racemic, optically-active, polymorphic, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein. The optically active forms can be prepared by, for example, resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase or by enzymatic resolution.
Examples of methods to obtain optically active materials include at least the following.
Chiral chromatography, including but not limited to simulated moving bed chromatography, is used in one embodiment. A wide variety of chiral stationary phases are commercially available.
III. Definitions
The term “independently” is used herein to indicate that the variable, which is independently applied, varies independently from application to application. Thus, in a compound such as R″XYR″, wherein R″ is “independently carbon or nitrogen,” both R″ can be carbon, both R″ can be nitrogen, or one R″ can be carbon and the other R″ nitrogen.
As used herein, the term “substantially free of” or “substantially in the absence of” refers to a nucleoside composition that includes at least 95% to 98% by weight, and even more preferably 99% to 100% by weight, of the designated enantiomer of that nucleoside. In a preferred embodiment, in the methods and compounds of this invention, the compounds are substantially free of enantiomers.
Similarly, the term “isolated” refers to a nucleoside composition that includes at least 85 or 90% by weight, preferably 95% to 98% by weight, and even more preferably 99% to 100% by weight, of the nucleoside, the remainder comprising other chemical species or enantiomers.
The term “alkyl,” as used herein, unless otherwise specified, refers to a saturated straight, branched, or cyclic, primary, secondary, or tertiary hydrocarbon. The term includes both substituted and unsubstituted alkyl groups. The alkyl group may be optionally substituted with any moiety that does not otherwise interfere with the reaction or that provides an improvement in the process, including but not limited to but limited to halo, haloalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene et al., Protective Groups in Organic Synthesis, John Wiley & Sons, Second Edition, 1991, hereby incorporated by reference. Specifically included are CF3 and CH2CF3.
Alkyl groups include, but are not limited to the radicals of methane, ethane, propane, cyclopropane, 2-methylpropane (isobutane), n-butane, 2,2-dimethylpropane (neopentane), cytobutane, 1,1 diraethylcyclopropane, 2-methylbutane, trans-1,2-dimethylcyclopropane, ethylcyclopropane, n-pentane, methylcyclobutane, cis-1,2-dimethylcyclopropane, spiropentane, cyclopentane, 2,2-dimethylbutane, 1,1,2-trimethylcyclopropane, 2,3-dimethylbutane, 2-methylpentane, 3-methylpentane, 1,2,3-trimethylcyclopropane, n-hexane, ethylcyclobutane, methylcyclopentane, 2,2dimethylpentane, 2,4-dimethylpentane, cyclohexane, 2,2,3-trimethylbutane, 3,3-dimethylpentane, 1,1-dimethylcyclopentane, 2,3-dimethylpentane, 2-methylhexane, trans-1,3-dimethylcyclopentane, cis-1,3-dimethylcyclopentane, 3-methylhexane, trans-1,2-dimethylcyclopentane, 3-ethylpentane, quadricyclane (quadricyclo[2,2,1,02,6,o3,5]heptane), n-heptane, 2,2,4-trimethylpentane, cis-1,2-dimethylcyclopentane, methylcyclohexane, ethylcyclopentane, 1,1,3-trimethylcyclopentane, 2,2-dimethylhexane, 2,5-dimethylhexane, 1,trans-2, cis-4trimethylcyclopentane, 2,4-dimethylhexane, 2,2,3-trimethylpentane, 1,trans-2,cis-3-trimethylcyclopentane, 3,3-dimethylhexane, 2,3,4-trimethylpentane, 1,1,2-trimethylcyclopentane, 2,3,3-trimethylpentane, 2,3-dimethylhexane, 3-ethyl-2-methylpentane, 1,cis-2,trans-4-trimethylcyclopentane, 1,cis-2,trans-3trimethylcyclopentane, 2-methylheptane, 4-methylheptane, 3,4-dimethylhexane, 1,cis-2,cis-4trimethylcyclopentane, 3-ethyl-3-methylpentane, 3-ethylhexane, 3-methylheptane, cylotheptane (suberane), trans-1,4-dimethylcyclohexane, 1,1-dimethylcyclohexane, cis-1,3-dimethylcychohexane, trans-1-ethyl-3-methylcyclopentane, trans-1-ethyl-2-methylcyclopentane, cis-1-ethyl-3-methylcyclopentane, 1-ethyl-1-methylcyclopentane, 2,2,4,4-tetramethylpentane, 1,cis-2-cis-3-trimethylcyclopentane, trans-1,2-dimethylcyclohexane, 2,2,5-trimethylhexane, trans-1,3-dimethylcyclohexane, n-octane, isopropylcyclopentane, 2,2,4-trimethylhexane, cis-1-ethyl-2-methylcyclopentane, cis-1,2-dimethylcyclohexane, 2,4,4-trimethylhexane, n-propylcyclopentane, 2,3,5-trimethylhexane, ethylcyclohexane, 2,2-dimethylheptane, 2,2,3,4-tetramethylpentane, 2,4-dimethylheptane, methylcycloheptane, 2,2,3-trimethylhexane, 4-ethyl-2-methylhexane, 3-ethyl-2.2-dimethylpentane, 4,4-dimethylheptane, 2,6-dimethylheptane, 2,5-dimethylheptane, 3,5-dimethylheptane, bicyclo[4.2.0]octane, cis-bicyclo[3.3.0]octane, 2,4-dimethyl-3-ethylpentane, 1,1,3-trimethylcyclohexane, 3,3-dimethylheptane, 2,2,5,5-tetramethylhexane, 2,3,3-trimethylhexane, 3-ethyl-2-methylhexane, trans-1,3,5-trimethylcyclohexane, 2,3,4-trimethylhexane, cis-1,3,5-trimethylcyclohexane, trans-1,2,4-trimethylcyclohexane, 2,2,3,3-tetramethylpentane, 4-ethyl-3-methylhexane, 3,3,4-trimethylhexane, 2,3-dimethylheptane, 3,4-dimethylheptane, 3-ethyl-3-methylhexane, 4-ethylheptane, 2,3,3,4-tetramethylpentane, 2,3-dimethyl-3-ethylpentane, trans-1,2,3-trimethylcyclohexane, 1-isopropyl-e-methylcyclopentane (pulegan), 4-methyloctane, 1-isopropyl-2-methylcyclopentane, 3-ethylheptane, 2-methyloctane, cis-1,2,3-trimethylcyclohexane, 3-methyloctane, 2,4,6-trimethylheptane, cis-1,2,4-trimethylcyclohexane, 3,3-diethylpentane, 2,2-dimethyl-4-ethylhexane, 2,2,4-trimethylheptane, 2,2,4,5-tetramethylhexane, 2,2,5-trimethylheptane, 2,2,6-trimethylheptane, 2,2,3,5-tetramethylhexane, nopinane (7,7-dimethylbicyclo[3.1.1]heptane), trans-1-ethyl-r-methylcyclohexane, cycloctane, 1-ethyl-2-methylcyclohexane, n-nonane, 1,3,3-trimethylbicyclo[2.2.1]heptane (fenchane), trans-1-ethyl-4-methylcyclohexane, cis-1,1,3,5-tetramethylcyclohexane, cis-1-ethyl-4-methylcyclohexane, 2,5,5-trimethylheptane, 2,4,4-trimethylheptane, 2,3,3,5-tetramethylhexane, 2,2,4,4-tetramethylhexane, isopropylcyclohexane, 1,1,2,2-tetramethylcyclohexane, 2,2,3,4-tetramethylhexane, 2,2-dimethyloctane, 3-ethyl-2,2,4-trimethylpentane, 3,3,5-trimethylheptane, 2,3,5-trimethylheptane, 2,4-dimethyloctane, d,l-cis-1-ethyl-3-methylcyclohexane, d,l-2,5-dimethyloctane, 1,1,3,5-tetramethylcyclohexane, n-butylcyclopentane, n-propylcyclohexane, 2,3,5-trimethylheptane, 2,5-dimethyl-3-ethylhexane, 2,4,5-trimethylheptane, 2,4-dimethyl-3-isopropylpentane, 2,2,3-trimethylheptane, 2,4-dimethyl-4-ethylhexane, 2,2-dimethyl-3-ethylhexane, 2,2,3,4,4-pentamethylpentane, 1,1,3,4-tetramethylcyclohexane, 5-ethyl-2-methylheptane, 2,7-dimethyloctane, 3,6-dimethyloctane, 3,5-dimethyloctane, 4-isopropylheptane, 2,3,3-trimethylheptane, 4-ethyl-2-methylheptane, 2,6-dimethyloctane, 2,2,3,3-tetramethylhexane, trans-1-isopropyl-4-methylcyclohexane (p-menthane), 4,4-dimethyloctane, 2,3,4,5-tetramethylhexane, 5-ethyl-e-methylheptane, 3,3-dimethyloctne, 4,5-dimethyloctane, 3,4-diethylhexane, 4-propylheptane, 1,1,4-trimethylcycloheptane (eucarvane), trans-1,2,3,5-tetramethylcyclohexane, 2,3,4,4-tetramethylhexane, 2,3,4-trimethylheptane, 3-isopropyl-2-methylhexane, 2,2,7-trimethylbicyclo[2.2.1]heptane (a-frenchane), 3-methylheptane, 2,4-dimethyl-3-ethylhexane, 3,4,4-trimethylheptane, 3,3,4-trimethylheptane, 3,4,5-trimethylheptane, 2,3-dimemthyl-4-ethylhexane, 1-methyl-e-propylcyclohexane, 2,3-dimethyloctane, d,l-pinane, 2,3,3,4-tetramethylhexane, 3,3-dimethyl-4-ethylhexane, 5-methylnonane, 4-methylnonane, 3-ethyl-2-methylheptane, 3,4-dimethyloctane, d-a-pinane, d,l-1-isopropyl-3-methylcyclohexane (d,l-m-menthane), 2,2,3,3,4-pentamethylpentane, trans-1,2,4,5-tetramethylcyclohexane, 3,3-diethylhexane, 2-methylnonane, d-1-isopropyl-3-methylcyclohexane (d-m-menthane), 3-ethyl-4-methylheptane, 4-ethyl-3-methylheptane, 4-ethyl-4-methylheptane, 1-β-pinane, 3-methylnonane, 3-ethyloctane, 4-ethyloctane, 3-ethyl-2,2,3-trimethylpentane, 1-1-isopropyl-3-methylcyclohexane (1-m-menthane)cis-1-isopropyl-4-methylcyclohexane (cis-p-menthane), cis-1,2,3,5-tetramethylcyclohexane, 2,3-dimethyl-3-ethylhexane, 1-isopropyl-4-methylcyclohexane (p-menthane), 3,4-dimethyl-3-ethylhexane, 3,3,4,4-tetramethylhexane, cyclononane, 1-isopropyl-2-methylcyclohexane (o-menthane), cis-1,2,4,5-tetramethylcyclohexane, 1-methyl-1-propylcyclohexane, n-decane, 1-methyl-4-propylcyclohexane, 1-methyl-2-propylcyclohexane, n-pentrylcyclopentane, n-butylcyclohexane, trans-decahydronaphthalene (trans-decalin), isoamylcyclohexane, cis-decahydronaphthalene (cis-decalin), n-undecane (n-hendecane), cyclodecane, n-pentylcyclohexane, n-hexylcyclopentane, 9-methyl-trans-decahydronaphthalene, 1,10-dimethyl-trans-decahydronaphthalene, 9-methyl-cis-decahydronaphthalene, n-dodecane, 1,10-dimethyl-cis-decahydronaphthalene, n-hexycyclohexane, n-heptylcyclopentane, 9-ethyl-trans-decahydronaphthalene, 9-ethyl-cis-decahydronaphthalene, 1-methyl-trans-decahydronaphthalene, n-tridecane, bicyclohexyl, n-octylcyclopentane, n-heptylcyclohexane, n-tetradecane, n-nonylcyclopentane, n-octylcyclohexane, n-pentadecane, n-decyclopentane, n-nonylcyclohexane, n-undecylcyclopentane (n-hendecylcyclopentane), n-decylcyclohexane, 2-methylheptadecane, n-dodecylcyclopentane, n-undecylcyclohexane (n-hendecylcyclohexane), n-tridecylcyclopentane, n-dodecylcyclohexane, n-tetradecylcyclopentane, pentadecyclcyclopentane, n-hexadecane (cetane), tridecylcyclohexane, hexadecicyclopentane, n-heptadecane, tetradecylcyclohexane, heptadecylcyclopentane, n-octadecane, pentadecylcyclohexane, octadecylcyclopentane, n-nonadecane, hexadecylcyclohexane, nonadecylcyclopentane, n-eicosane, heptadecylcyclohexane, eicosylcyclopentane, n-heneicosane, octadecylcyclohexane, heneicosylcyclopentane, n-docosane, docosylcyclopentane, nonadecylcyclohexane, n-tricosane, eicosylcyclohexane, tricosylcyclopentane, n-tetracosane, tetracosylcyclopentane, heneicosylcyclohexane, n-pentacosane, pentacosylcyclopentane, docosylcyclohexane, hexacosylcyclopentane, notricyclene (tricyclo[2.2.1.02,6]heptane), n-hexacosane, cyclohexadecane, tricosylcyclohexane, heptacosylcyclopentane, n-heptacosane, tetracosylcyclohexane, cyclopentadecane, octacosylcyclopentane, n-octacosane, pentacosylcyclohexane, nonacosylcyclopentane, n-nonacosane, hexacosylcyclohexane, triacontylcyclopentane, d,l-isobornane (2,2,3-trimethylbicyclo[2.2.2]heptane), n-triacontane, heptacosylcyclohexane, hentriacontylcyclopentane, n-hentriacontane, octacosylcyclohexane, dotriacontylcyclopentane, n-dotriacontane (bicetyl), noncosylcyclohexane, tritriacontylcyclopentane, tritriacontane, triacontylcyclohexane, tetratriacontylcyclopentane, tetratriacontane, 28-methylnonacosane, hentriacontylcyclohexane, pentatriacontylcyclopentane, pentatriacontane, dotriacontylcyclohexane, hexatriacontylcyclopentane, hexatriacontane, tritriacontylcyclohexane, heptatriacontane, tetratriacontylcyclohexane, octatriacontane, pentatriacontylcyclohexane, nonatriacontane, hexatriacontylcyclohexane, tetracontane, norbornane (bicyclo[2.2.1]heptane], 2,2,3,3-tetramethylbutane, bornane (camphane), and adamantane. It is understood to those of ordinary skill in the art that the relevant alkyl radical is named by replacing the suffix “-ane” with the suffix “-yl”.
The term “alkenyl” refers to an unsaturated, hydrocarbon radical, linear or branched, in so much as it contains one or more double bonds. The alkenyl group disclosed herein can be optionally substituted with any moiety that does not adversely affect the reaction process, including but not limited to but not limited to alkyl, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid or phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene et al., Protective Groups in Organic Synthesis, John Wiley & Sons, Second Edition, 1991, hereby incorporated by reference. Non-limiting examples of alkenyl groups include methylene, ethylene, methylethylene, isopropylidene, 1,2-ethane-diyl, 1,1-ethane-diyl, 1,3-propane-diyl, 1,2-propane-diyl, 1,3-butane-diyl, and 1,4-butane-diyl.
The term “alkynyl” refers to an unsaturated, acyclic hydrocarbon radical, linear or branched, in so much as it contains one or more triple bonds. The alkynyl group may be optionally substituted with any moiety that does not adversely affect the reaction process, including but not limited to but not limited to hydroxyl, halo (F, Cl, Br, I), perfluoro alkyl including but not limited to trifluoromethyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, acyl, amido, carboxamido, carboxylate, thiol, alkylthio, azido, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene et al., Protective Groups in Organic Synthesis, John Wiley & Sons, Second Edition, 1991, hereby incorporated by reference. Non-limiting examples of suitable alkynyl groups include ethynyl, propynyl, hydroxypropynyl, butyn-1-yl, butyn-2-yl, pentyn-1-yl, pentyn-2-yl, 4-methoxypentyn-2-yl, 3-methylbutyn-1-yl, hexyn-1-yl, hexyn-2-yl, and hexyn-3-yl, 3,3-dimethylbutyn-1-yl radicals.
The term “alkylamino” or “arylamino” refers to an amino group that has one or two alkyl or aryl substituents, respectively.
The term “protected” as used herein and unless otherwise defined refers to a group that is added to an oxygen, nitrogen, or phosphorus atom to prevent its further reaction or for other purposes. A wide variety of oxygen and nitrogen protecting groups are known to those skilled in the art of organic synthesis.
The term “aryl”, alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused. Non-limiting examples of aryl include phenyl, biphenyl, or naphthyl, or the following aromatic group that remains after the removal of a hydrogen from the aromatic ring: benzene, toluene, ethylbenzene, 1,4-xylene, 1,3-xylene, 1,2-xylene, isopropylbenzene (cumene), n-propylbenzene, 1-ethyl-3-methylbenzene (m-ethyltoluene), 1-ethyl-4-methylbenzene (p-ethyltoluene), 1,3,5-trimethylbenzene (mesitylene), 1-ethyl-2-methylbenzene (o-ethyltoluene), tert-butylbenzene, 1,2,4-trimethylbenzene (pseudodocumene), isobutylbenzene, sec-butylbenzene, 3-isopropylmethylbenzene (3-isopropyltoluene; m-cymene), 1,2,3-trimethylbenzene (hemimellitene), trans-propenylbenzene, indane, 4-isopropyl-1-methylbenzene (4-isopropyltoluene; 4-cymene), 2-isopropyl-methylbenzene (2-isopropyltoluene; 2-cymene), 1,3-diethbenzene, 1 methyl-3-proplybenzene (m-propyltoluene), indene, n-butylbenzene, 1-methyl-4-propylbenzene (p-propyltoluene), 1,2-diethylbenzene, 1,4-diethylbenzene, 1,3-dimethyl-5-ethylbenzene, 1-methyl-2-propylbenzene (o-propyltoluene), 2,2-dimethyl-1-phenylpropane (neopentylbenzene), 1,4-dimethyl-2-ethylbenzene, 2-methylindane, 3-methyl-2-phenylbutane, 1-methylindane, 1,3-dimethyl-4-ethylbenzene, 3-tert-butyl-menthylbenzene, (3-tert-butyltoluene), 1,2-dimethyl-4-ethylbenzene, 1,3-dimethyl-2-ethylbenzene, 3-phenylpentane, 1-ethyl-3-isopropylbenzene, 2-methyl-2-phenylbutane, 4-tert-butyl1-methylbenzene (4-tert-butyltoluene), 1-ethyl-2-isopropylbenzene, 2-phenylpentane, 1,2-dimethyl-3-ethybenzene, 3-sec-butyl-1-methylbenzene, (3-sec-butylotoluene), 3-isobutyl-1-methylbenzene, (3-isobutyltoluene), d-2-methyl-1-phenylbutane, 1,3-dimethyl-5-isopropyl-benzene, 2-phenyl-cis-2-butene, 4-isobutyl-methylblenzene (p-isobulyltoluene), 2-sec-butyl-1-methylbenzene (2-sec-butyltoluene), 2-isobutyl-1-methylblenzene (o-isobutyltoluene), 1,4-dimethyl-2-isopropyl-benzene, 1-ethyl-4-isopropylbenzene, d,l-2-methyl-1-phenylbutane, 1,2,3,5-tetramethylbenzene (isodurene), 3-methyl-1-phenylbutane (isopentylbenzene), 1,3-dimethyl-2-isopropylbenzene, 1,3-dimethyl-4-isopropylbenzene), 3-methylindene, 4-sec-butyl-1-methylbenzene (p-sec-butyltoluene), 2-tert-butyl-1-methylbenzene (2-tert-butyltoluene), 3,5-diethyl-1-methylbenzene (3,5-diethyltoluene), 2-butyl-1-methylbenzene (2 butyltoluene), 1-ethyl-3-propylbenzene, 1,2-dimethyl-4-isopropylbenzene, 1,2-dimethyl-3-isopropylbenzene, 1-ethyl-2-propylbenzene, 1,3-di-isopropyllbenzene, 1,2-diethyl-4-methylbenzene, 1,2-di-isopropylbenzene, 1,4-dimethyl-2-proplybenzene, 1,2,3,4-tetramethylbenzene (prehnitene), 1-ethyl-4-propylbenzene, 3-butyl-1-methlybenzene (m-butyltoluene), 2,4-diethyl-1-methylbenzene (2,4-diethyltoluene), n-pentylbenzene, 3-methyl-3-phenylpentane, 1,3-dimethyl-5-tert-butylbenzene, 1,3-dimethyl-4-propylbenzene, 1,2-diethyl-3-methylbenzene, 4-butyl-1-methylbenzene, 4-butyl-1-methylbenzene, 1,2,3,4-tetrahydronaphthalene, 1,3-diethyl-2-propylbenzene, 2,6-diethyl-1-methylbenzene, 1,2-dimethyl-4-propylbenzene, 1,3-dimethyl-5-propylbenzene, 2-methyl-3-phenylpentane, 4-tert-butyl-1,3-dimethylbenzene, 1,4-di-isopropylbenzene, 1,2-dimethyl-3-propylbenzene, 1-teri-butyl-4-ethylbenzene, d,l-3-phenylhexane, 2-ethyly-1,3,5-trimethyl-benzene, 3-ethyly-4-isopropyl-1-methylbenzene, 5-ethyl-1,2,4-trimethylbenzene, 6-ethyl-1-2,4-trimethylbenzene, 2-phenylhexane, 2-methyl-1-phenylpentane, 4-isopropyl-1-propylbenzene, 1,3-dipropylbenzene, 5-ethyl-1,2,3-trimethylbenzene, 1,2,4-triethylbenzene, 1,3,5-triethylbenzene, 2-methyl-1,2,3,4-tetrahydronaphthalene, 1-methyl-1,2,3,4-tetrahydronaphthalene, 4-ethyl-1,2,3-trimethylbenzene, 1,4-dipropylbenzene, 3-methyl-1-phenylpentane, 2-propyl-1,3,5-trimethylbenzene, 1,1-dimeihyl-1,2,3,4-tetrahydronaphthalene, 3-tert-butyl-1-isopropylbenzene, 1-methyl-3-pentylbenzene, 4-tert-butyl-1-isopropylbenzene, 2-methyl-2-phenylhexane, 2,4-di-isopropyl-1-methylbenzene, 3-methyl-3-phenylhexane, n-hexylbenzene, 3-phenylheptane, 2,6-di-isopropyl-1-methylbenzene, 5-propyl-1,2,4-trimethylbenzene, 6-methyl-1,2,3,4-tetrahydronaphthalene, 2,2-dimethyl-1,2,3,4-tetrahydronaphthalene, 2-phenylheptane, 5-methyl-1,2,3,4-tetrahydronaphthalene, 2-ethyl-1,2,3,4-tetrahydronaphthalene, cyclohexylbenzene, 1-ethyl-1,2,3,4-tetrahydronaphthalene, 2,5-dimethyl-1,2,3,4-tetrahydronaphthalene, 2,8-dimethyl-1,2,3,4-tetrahydronaphthalene, 2,7-dimethyl-1,2,3,4-tetrahydronaphthalene, 2,6-dimethyl-1,2,3,4-tetrahydronaphthalene, 1,4-di-sec-butylbenzene, 1,5-dimethyl-1,2,3,4-tetrahydronaphthalene, 3-ethyl-3-phenylhexane, 6-ethyl-1,2,3,4-tetrahydronaphthalene, 2-methyl-1-phenyl-1-butene, 5-ethyl-1,2,3,4-tetrahydronaphthalene, n-heptylbenzene, 1-methylnaphthalene, 5,6-dimethyl-1,2,3,4-tetrahydronaphthalene, 6,7-dimethyl-1,2,3,4-tetrahydronaphthalene, 5,7-dimethyl-1,2,3,4-tetrahydronaphthalene, 2-ethylnaphthalene, 1-7-dimethylnaphthalene, 1,6-dimethylnaphthalene, 1,3-dimethylnaphthalene, n-octylbenzene, 1-allylnaphthalene, 1-isopropylnaphthalene, 1,4-dimethylnaphthalene, 1,1-diphenylethane, 2-isopropylnaphthalene, 2-propylnaphthalene, 1-propylnaphthalene, 1,3,7-trimethylnaphthalene, 1-isopropyl-7-methylnaphthalene, n-nonylbenzene, 2-butylnaphthalene, 2-tert-butylnaphthalene, 1-tert-butylnaphthalene, 1-butylnaphthalene, 4,5-benzindane, n-decylbenzene, 1-pentylnaphthalene, 2-pentylnaphthalene, n-undecylbenzene, 1-hexylnaphthalene, 2-hexylnaphthalene, n-dodecylbenzene, 1-heptylnaphthalene, 2-heptylnaphthalene, tridecylbenzene, 1-octylnaphthalene, 2-octylnaphthalene, 1-nonylnaphthalene, 2-nonylnaphthalene, 1-decylnaphthalene, 1,2,6-trimethylnaphthalene, diphenylmethane, 1,2,3-trimethylnaphthalene, 1,6,7-trimethylnaphthalene, 2-isopropylazulene, 1,4-dimethyl-7-isopropylazulene, 2,6-dimethylphenanthrene, 1,2,5-trimethylnaphthalene, 1-propylphenanthrene, 5-isopropylazulene, 5-isopropylazulene, 2-propylphenanthrene, 2-methylnaphthalene, 1-ethyl-5-methylnaphthalene, 9-isopropylnaphthalene, 6-isopropylazulene, 2-ethyl-6-methylnaphthalene, 2-isopropylphenanthrene, 6-isopropyl-1-methylphenanthrene, 2-ethylazulene, 2,5,-dimethylphenanthrene, 1,3,5-trimethylnaphthalene, 3-ethyl-6-methylphenanthrene, 2-methylazulene, 1,3,8-trimethylnaphthalene; 4-methylphenanthrene, 1,4-dimethylphenanthrene, bibenzyl, methylenefluorene, 3,5-dimethylphenanthrene, 1,3-dimethylazulene, 7-methyl-3,4-benzphenanthrene, pentamethylbenzene, 1,2,4-trimethylnaphthalene, 3,3-dimethylstilbene, 1,4,5,7-tetramethylnaphthalene, 1,2,4,8-tetramethylnaphthalene, 2,9-dimethylphenanthrene, 1,5-dimethylphenanthrene, 2-benzylnaphthalene, 1-benzylnaphthalene, 1-benzylnaphthalene, 1,2-dimethylazulene, 9-propylphenanthrene, 1,7-dimethyl-4-isopropylnaphthalene, 3-methylphenanthrene, 3,4-dimethylphenanthrene, 1-ethylphenanthrene, symdiphenylacetylene, 9-ethylphenanthrene, 1,4,5-trimethylnaphthalene, 4-methylfluorene, 1,4,6,7-tretramethylnaphthalene, 1,2,3-trimethylphenanthrene, 1,8-dimethylnaphthalene, 8-methyl-3,4-benzphenanthrene, 2-ethylphenanthrene, 3,4-benzphenanthrene, 1,3,7-trimethylphenanthrene, 4-isopropyl-1-methylphenanthrene, 4,8-dimethylazulene, biphenyl, 2-methyl-3,4-benzphenanthrene, 3-methylpyrene, 1,4,7-trimethylphenanthrene, 1,4-dimethylanthracene, 4,9-dimethyl-1,2-benzanthracene, benzalfluorene, 1,3-dimethylphenanthrene, 1-methyl-3,4-benzphenanthrene, 3-isopropyl-1-methylphenanthrene, 1,2-binaphthyl, 2,3-dimethylphenanthrene, 1-ethyl-2-methylphenanthrene, 1,5-dimethylnaphthalene, 6-methyl-3,4-benzphenanthrene, naphthalene, 1,3,6,8-tetramethylnaphthalene, 1-ethyl-7methylphenanthrene, 9-methylanthracene, 1-isopropyl-7-methylphenanthrene, 6-methylazulene, 1,3-dimethylanthracene, 2,2-dimethylstilbene, 1-methylanthracene, 1,7-dimethylphenanthrene, 1,6-diphenylnaphthalene, 1,6-dimethylphenanthrene, 1,9-dimethylphenanthrene, 9-methylphenanthrene, 1,2,10-trimethylanthracene, 7-ethyl-1-methylphenanthrene, triphenylmethane, 5-isopropylnaphthanthracene, 3,9-dimethyl-1,2-benzanthracene, 5,6-benzindane, 12-isopropylnaphthanthracene, acenaphthene, 2,7-dimethylnaphthalene, 7-isopropyl-1-methylfluorene, azulene, retene, phenanthrene, 2,7-dimethfylphenanthrene, 2,3,6-trimethfylnaphthalene, 2-phenylnaphthalene, 1,2,3,4-tetrahydroanthracene, 2,3-dimethylnaphthalene, ethylidenefluorene, 1,7-dimethylfuorene, 1,1-dinaphthylmethane, fluoranthrene, 2,6-dimethylnaphthalene, 2,4-dimethylphenanthrene, fluorene, 4,10-dimethyl-1,2-benzanthracene, 4h-cyclopenta(def) phenanthrene, 1,3,8-trimethylphenanthrene, 11-methylnaphthanthracene, 5-methylchrysene, 1,2,5,6-tetramethylnaphthalene, cyclohept(fg)acenaphthene, 1,2,7-trimethylphenanthrene, 1,10-dimethyl-1,2-dibenzanthracene, 9,10-dimethyl-1-benzanthracene, benz(bc)aceanthrylene, 1-methylphenanthrene, 1,6,7-trimethylphenanthrene, 1,1-diacenaphthene, trans-stilbene, 3,4-benzflurorene, 9-isopropylnaphthanthracene, 6-methylnaphthanthracene, 5,8-dimethyl-1,2-bezanthracene, 8-isopropylnaphthanthracene, 1,4,5,8-tetramethylnaphthalene, 12-methylnaphthanthracene, 2-methyl-1,2-benzpyrene, 1,5-dimethylanthracene, 7-methylnaphthanthracene, 3,6-dimethylphenanthrene, 5-methyl-3,4-benzphenanthrene, 1,4-dimethylchrysene, 1,2-dimethylphenanthrene, 8,10-dimethyl-1,2-benzanthracene, 1,2,8-trimethylphenanthrene, 3-methyl-1,2-benzpyrene, 9-methyl-1,2-benzpyrene, 9-phenylfluorene, 2-methylnaphthanthracene, pyrene, 9-methylnaphthanthracene, 4-methylchrysene, trans-trans-1,4-diphenyl-1,3-butadiene, cinnamalfluorene, 5-methylnaphthanthracene, 1,2-benzanthracene, 8-methylnaphthanthracene, 1,1-binaphthyl, di-1-naphthastibene, 6-methylchrysene, 3-methylnaphthanthracene, 2,6-dimethyl-1,2-benzanthracene, cyclopentadienophenanthrene, 10,11-benzfluoranthene, hexamethylbenzene, 3-methylchrysene, cholanthrene, 6-methyl-1,2-benzpyrene, 6,7-dimethyl-1,2-benzanthracene, 1,2-benzpyrene, 5,10-dimethyl-1,2-benzanthracene, 4,5-benzpyrene, 9,10-dimethylanthracene, 10-methylnaphthanthracene, 5,6-dimethyl-1,2-benzanthracene, 2,2-binaphthyl, 1,2-benfluorene, 1,8-dimethylphenanthrene, 8-methyl-1,2-benzpyrene, bifluorenylidene, 1,2,7,8-dibenzanthracene, 4-methylnaphthanthracene, 1,2,3,4-dibenzanthracene, di-2-fluorenylmethane, 2,3-benzfluorene, 5-methyl-1,2-benzpyrene, anthracene, 11,12-benzfluoranthene, 4-methyl-1,2-benzpyrene, 2,8-dimethylchrysene, 2-methylchrysene, 6,12-dimethylchrysene, 1,2-benzphenanthrene, di-2-naphthastilbene, 1-methylchrysene, 2,3,6,7-dibenzphenanthrene, 2,3,5,6-dibenzphenanthrene, 1,2,5,6-dibenzanthracene, perylene, picene, 1,2,3,4,5,6,7,8-tetrabenzanthracene, and coronene. The term aryl includes both substituted and unsubstituted moieties. The aryl group may be optionally substituted with any moiety that does not adversely affect the process, including but not limited to but not limited to halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrazine, carbamate, phosphonic acid, phosphonate, or any other viable functional group that does not inhibit the pharmacological activity of this compound, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene et al., Protective Groups in Organic Synthesis, John Wiley & Sons, Second Edition, 1991, hereby incorporated by reference. Non-limiting examples of substituted aryl include heteroarylamino, N-aryl-N-alkylamino, N-heteroarylamino-N-alkylamino, heteroaralkoxy, arylamino, aralkylamino, arylthio, monoarylamidosulfonyl, arylsulfonamido, diarylamidosulfonyl, monoaryl amidosulfonyl, arylsulfinyl, arylsulfonyl, heteroarylthio, heteroarylsulfinyl, heteroarylsulfonyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, hydroxyaralkyl, hydoxyheteroaralkyl, haloalkoxyalkyl, aryl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, saturated heterocyclyl, partially saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, and heteroarylalkenyl, carboaralkoxy. The terms “alkaryl” or “alkylaryl” refer to an alkyl group with an aryl substituent. The terms “aralkyl” or “arylalkyl” refer to an aryl group with an alkyl substituent.
The term “halo,” as used herein, includes chloro, bromo, iodo and fluoro.
The term “acyl” refers to a carboxylic acid ester in which the non-carbonyl moiety of the ester group is selected from straight, branched, or cyclic alkyl or lower alkyl, alkoxyalkyl including but not limited to methoxymethyl, aralkyl including but not limited to benzyl, aryloxyalkyl such as phenoxymethyl, aryl including but not limited to phenyl optionally substituted with halogen (F, Cl, Br, I), alkyl (including but not limited to C1, C2, C3, and C4) or alkoxy (including but not limited to C1, C2, C3, and C4), sulfonate esters such as alkyl or aralkyl sulphonyl including but not limited to methanesulfonyl, the mono, di or triphosphate ester, trityl or monomethoxytrityl, substituted benzyl, trialkylsilyl (e.g., dimethyl-t-butylsilyl) or diphenylmethylsilyl. Aryl groups in the esters optimally comprise a phenyl group. The term “lower acyl” refers to an acyl group in which the non-carbonyl moiety is lower alkyl.
The terms “alkoxy” and “alkoxyalkyl” embrace linear or branched oxy-containing radicals having alkyl moieties, such as methoxy radical. The term “alkoxyalkyl” also embraces alkyl radicals having one or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl radicals. The “alkoxy” radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide “haloalkoxy” radicals. Examples of such radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, difluoromethoxy, trifluoroethoxy, fluoroethoxy, tetrafluoroethoxy, pentafluoroethoxy, and fluoropropoxy.
The term “alkylamino” denotes “monoalkylamino” and “dialkylamino” containing one or two alkyl radicals, respectively, attached to an amino radical. The terms arylamino denotes “monoarylamino” and “diarylamino” containing one or two aryl radicals, respectively, attached to an amino radical. The term “aralkylamino”, embraces aralkyl radicals attached to an amino radical. The term aralkylamino denotes “monoaralkylamino” and “diaralkylamino” containing one or two aralkyl radicals, respectively, attached to an amino radical. The term aralkylamino further denotes “monoaralkyl monoalkylamino” containing one aralkyl radical and one alkyl radical attached to an amino radical.
The term “heteroatom,” as used herein, refers to oxygen, sulfur, nitrogen and phosphorus.
The terms “heteroaryl” or “heteroaromatic,” as used herein, refer to an aromatic that includes at least one sulfur, oxygen, nitrogen or phosphorus in the aromatic ring.
The term “heterocyclic” refers to a nonaromatic cyclic group wherein there is at least one heteroatom, such as oxygen, sulfur, nitrogen, or phosphorus in the ring.
Nonlimiting examples of heteroaryl and heterocyclic groups include furyl, furanyl, pyridyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, benzofuranyl, benzothiophenyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbazolyl, oxazolyl, thiazolyl, isothiazolyl, 1,2,4-thiadiazolyl, isooxazolyl, pyrrolyl, quinazolinyl, cinnolinyl, phthalazinyl, xanthinyl, hypoxanthinyl, thiophene, furan, pyrrole, isopyrrole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, oxazole, isoxazole, thiazole, isothiazole, pyrimidine or pyridazine, and pteridinyl, aziridines, thiazole, isothiazole, 1,2,3-oxadiazole, thiazine, pyridine, pyrazine, piperazine, pyrrolidine, oxaziranes, phenazine, phenothiazine, morpholinyl, pyrazolyl, pyridazinyl, pyrazinyl, quinoxalinyl, xanthinyl, hypoxanthinyl, pteridinyl, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, pyrazolopyrimidinyl, adenine, N6-alkylpurines, N6-benzylpurine, N6-halopurine, N6-vinypurine, N6-acetylenic purine, N6-acyl purine,N6-hydroxyalkyl purine, N6-thioalkyl purine, thymine, cytosine, 6-azapyrimidine, 2-mercaptopyrmidine, uracil, N5-alkylpyrimidines; N5-benzylpyrimidines, N5-halopyrimidines, N5-vinylpyrimidine, N5-acetylenic pyrimidine, N5-acyl pyrimidine, N5-hydroxyalkyl purine, and N6-thioalkyl purine, and isoxazolyl. The heteroaromatic group can be optionally substituted as described above for aryl. The heterocyclic or heteroaromatic group can be optionally substituted with one or more substituent selected from halogen (F, Cl, Br, I), haloalkyl, alkyl, alkoxy, hydroxy, carboxyl derivatives, amido, amino, alkylamino, dialkylamino. The heteroaromatic can be partially or totally hydrogenated as desired. As a nonlimiting example, dihydropyridine can be used in place of pyridine. Functional oxygen and nitrogen groups on the heterocyclic or heteroaryl group can be protected as necessary or desired. Suitable protecting groups are well known to those skilled in the art, and include trimethylsilyl, dimethylhexylsilyl, t-butyldimethylsilyl, and t-butyldiphenylsilyl, trityl or substituted trityl, alkyl groups, acyl groups such as acetyl and propionyl, methanesulfonyl, and p-toluenelsulfonyl. The heterocyclic or heteroaromatic group can be substituted with any moiety that does not adversely affect the reaction, including but not limited to but not limited to those described above for aryl.
The term “host,” as used herein, refers to a unicellular or multicellular organism in which the virus can replicate, including but not limited to cell lines and animals, and preferably a human. Alternatively, the host can be carrying a part of the viral genome, whose replication or function can be altered by the compounds of the present invention. The term host specifically refers to infected cells, cells transfected with all or part of the viral genome and animals, in particular, primates (including but not limited to chimpanzees) and humans. In most animal applications of the present invention, the host is a human patient. Veterinary applications, in certain indications, however, are clearly anticipated by the present invention (such as chimpanzees).
The term “pharmaceutically acceptable salt or prodrug” is used throughout the specification to describe any pharmaceutically acceptable form (such as an ester, phosphate ester, salt of an ester or a related group) of a nucleoside compound which, upon administration to a patient, provides the nucleoside compound. Pharmaceutically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic bases and acids. Suitable salts include those derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium and magnesium, among numerous other acids well known in the pharmaceutical art. Pharmaceutically acceptable prodrugs refer to a compound that is metabolized, for example hydrolyzed or oxidized, in the host to form the compound of the present invention. Typical examples of prodrugs include compounds that have biologically labile protecting groups on a functional moiety of the active compound. Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, dephosphorylated to produce the active compound. The compounds of this invention possess antiviral activity against Flaviviridae, or are metabolized to a compound that exhibits such activity.
Prodrugs also include natural or unnatural amino acid esters of the disclosed nucleosides (see, e.g., European Patent Specification No. 99493, the text of which is incorporated by reference, which describes amino acid esters of acyclovir, specifically the glycine and alanine esters which show improved water-solubility compared with acyclovir itself, and U.S. Pat. No. 4,957,924 (Beauchamp), which discloses the valine ester of acyclovir, characterized by side-chain branching adjacent to the a-carbon atom, which showed improved bioavailability after oral administration compared with the alanine and glycine esters). A process for preparing such amino acid esters is disclosed in U.S. Pat. No. 4,957,924 (Beauchamp), the text of which is incorporated by reference. As an alternative to the use of valine itself, a functional equivalent of the amino acid may be used (e.g., an acid halide such as the acid chloride, or an acid anhydride). In such a case, to avoid undesirable side-reactions, it may be is advantageous to use an amino-protected derivative.
IV. Nucleotide Salt or Prodrug Formulations
In cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the compound as a pharmaceutically acceptable salt may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids, which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, α-ketoglutarate and α-glycerophosphate. Suitable inorganic salts may also be formed, including but not limited to, sulfate, nitrate, bicarbonate and carbonate salts.
Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid, affording a physiologically acceptable anion. Alkali metal (e.g., sodium, potassium or lithium) or alkaline earth metal (e.g., calcium) salts of carboxylic acids can also be made.
Any of the nucleosides described herein can be administered as a nucleotide prodrug to increase the activity, bioavailability, stability or otherwise alter the properties of the nucleoside. A number of nucleotide prodrug ligands are known. In general, alkylation, acylation or other lipophilic modification of the mono, di or triphosphate of the nucleoside will increase the stability of the nucleotide. Examples of substituent groups that can replace one or more hydrogens on the phosphate moiety are alkyl, aryl, steroids, carbohydrates, including but not limited to sugars, 1,2-diacylglycerol and alcohols. Many are described in R. Jones & N. Bischofberger, Antiviral Research, 27 (1995) 1-17. Any of these can be used in combination with the disclosed nucleosides to achieve a desired effect.
The active nucleoside can also be provided as a 5′-phosphoether lipid or a 5′-ether lipid, as disclosed in the following references, which are incorporated by reference: Kucera, L. S., N. Iyer, E. Leake, A. Raben, Modest E. K., D. L. W., and C. Piantadosi, “Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation,” AIDS Res. Hum. Retroviruses, 1990, 6, 491-501; Piantadosi, C., J. Marasco C. J., S. L. Morris-Naischke, K. L. Meyer, F. Gumus, J. R. Surles, K. S. Ishaq, L. S. Kucera, N. Iyer, C. A. Wallen, S. Piantadosi, and E. J. Modest, “Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV activity,” J. Med. Chem., 1991, 34, 1408-1414; Hosteller, K. Y., D. D. Richman, D. A. Carson, L. M. Stuhmiller, G. M. T. van Wijk, and H. van den Bosch, “Greatly enhanced inhibition of human immunodeficiency virus type 1 replication in CEM and HT4-6C cells by 3′-deoxythymidine diphosphate dimyristoylglycerol, a lipid prodrug of 3, -deoxythymidine,” Antimicrob. Agents Chemother., 1992, 36, 2025-2029; Hostetler, K. Y., L. M. Stuhmiller, H. B. Lenting, H. van den Bosch, and D. D. Ricbman, “Synthesis and antiretroviral activity of phospholipid analogs of azidothymidine and other antiviral nucleosides.” J. Biol. Chem., 1990, 265, 61127.
Nonlimiting examples of U.S. patents that disclose suitable lipophilic substituents that can be covalently incorporated into the nucleoside, preferably at the 5′-OH position of the nucleoside or lipophilic preparations, include U.S. Pat. No. 5,149,794 (Yatvin et al.); U.S. Pat. No. 5,194,654 (Hostetler et al.), U.S. Pat. No. 5,223,263 (Hostetler et al.); U.S. Pat. No. 5,256,641 (Yatvin et al.); U.S. Pat. No. 5,411,947 (Hostetler et al.); U.S. Pat. No. 5,463,092 (Hostetler et al.); U.S. Pat. No. 5,543,389 (Yatvin et al.); U.S. Pat. No. 5,543,390 (Yatvin et al.); U.S. Pat. No. 5,543,391 (Yatvin et al.); and U.S. Pat. No. 5,554,728 (Basava et al.), all of which are incorporated by reference. Foreign patent applications that disclose lipophilic substituents that can be attached to nucleosides of the present invention, or lipophilic preparations, include WO 89/02733, WO 90/00555, WO 91/16920, WO 91/18914, WO 93/00910, WO 94/26273, WO 96/15132, EP 0 350 287, EP 93917054.4, and WO 91/19721.
V. Combination or Alternation Therapy
In another embodiment for the treatment of HIV or HBV infection, the active compound or its prodrug or salt can be administered in combination or alternation with another antiviral agent, such as another active anti-HIV or anti-HBV agent, including but not limited to those of the formulae above, others listed below or known in the art. In general, in combination therapy, effective dosages of two or more agents are administered together, whereas during alternation therapy, an effective dosage of each agent is administered serially. The dosage will depend on absorption, inactivation and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens and schedules should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.
Nonlimiting examples of antiviral agents that can be used in combination with the compounds disclosed herein include those in the tables below.
Hepatitis B Therapies
Drug Name
Drug Class
Company
Intron A (interferon alfa-
interferon
Schering-Plough
2b)
Epivir-HBV (lamivudine;
nucleoside analogue
GlaxoSmithKline
3TC)
Hepsera (Adefovir
nucleoside analogue
Gilead Sciences
Dipivoxi)″
Coviracil (emtricitabine;
nucleoside analogue
Triangle
FTC)
Pharmaceuticals
Entecavir
nucleoside analogue
Bristol-Myers Squibb
Clevudine (L-FMAU)
nucleoside analogue
Triangle
Pharmaceuticals
ACH 126, 443 (L-Fd4C)
nucleoside analogue
Achillion
Pharmaceuticals
AM 365
nucleoside analogue
Amrad
Amdoxovir (formerly
nucleoside analogue
Triangle
DAPD)
Pharmaceuticals
LdT (telbivudine)
nucleoside analogue
Idenix
XTL 001
monoclonal
XTL Biopharm
antibody
Theradigm
Immune stimulant
Epimmune
Zadaxin (thymosin)
Immune stimulant
SciClone
EHT 899
viral protein
Enzo Biochem
HBV DNA vaccine
Immune stimulant
PowderJect (UK)
MCC 478
nucleoside analogue
Eli Lilly
valLdC (valtorcitabine)
nucleoside analogue
Idenix
ICN 2001
nucleoside analogue
ICN
Fluro L and D nucleosides
nucleoside analogue
Pharmasset
Racivir
nucleoside analogue
Pharmasset
Robustaflavone
nucleoside analogue
Advanced Life
Sciences
Penciclovir
DXG
HDP-P-acyclovir
LM-019c
CS-109
PS-019
PS-018
ara-AMP prodrugs
HBV/MF59
Hammerhead ribozymes
Glycosidase Inhibitors
Pegylated Interferon
Human Monoclonal
Antibodies
Famciclovir
HIV Therapies: Protease Inhibitors (PIs)
Brand
Pharmaceutical
Name
Generic Name
Abbreviation
Company
Invirase ®
saquinavir (Hard
SQV (HGC)
Hoffman-La Roche
Gel Cap)
Fortovase ®
saquinavir (Soft Gel
SQV (SGC)
Hoffman-La Roche
Cap)
Norvir ®
ritonavir
RTV
Abbott Laboratories
Crixivan ®
indinavir
IDV
Merck & Co.
Viracept ®
nelfinavir
NFV
Pfizer
Agenerase ®
amprenavir
APV
GlaxoSmithKline
Kaletra ®
lopinavir + ritonavir
LPV
Abbott Laboratories
fosamprenavir
GlaxoSmithKline
tipranavir
TBV
Boehringer Ingelheim
atazanavir
Bristol-Myers Squibb
HIV Therapies: Nucleoside/Nucleotide Reverse Transcriptase
Inhibitors (NRTIs)
Brand
Pharmaceutical
Name
Generic Name
Abbreviation
Company
Retrovir ®
zidovudine
AZT or ZDV
GlaxoSmithKline
Epivir ®
lamivudine
3TC
GlaxoSmithKline
Combivir ®
zidovudine +
AZT + 3TC
GlaxoSmithKline
lamivudine
Trizivir ®
abacavir +
ABC +
GlaxoSmithKline
zidovudine +
AZT + 3TC
lamivudine
Ziagen ®
abacavir
ABC
GlaxoSmithKline
Hivid ®
zalcitabine
ddC
Hoffman-La Roche
Videx ®
didanosine: buffered
ddI
Bristol-Myers
versions
Squibb
Videx ® EC
didanosine: delayed-
ddI
Bristol-Myers
release capsules
Squibb
Zerit ®
stavudine
d4T
Bristol-Myers
Squibb
Viread ™
tenofovir disoproxil
TDF or
Gilead Sciences
fumarate (DF)
Bis(POC)
PMPA
Coviracil ™
emtricitabine
FTC
Triangle
Pharmaceuticals
amdoxovir
DAPD
Triangle
Pharmaceuticals
HIV Therapies: Non-Nucleoside Reverse
Transcriptase Inhibitors (NNRTIs)
Brand Name
Generic Name
Abbreviation
Pharmaceutical Company
Viramune ®
nevirapine
NVP
Boehringer Ingelheim
Rescriptor ®
delavirdine
DLV
Pfizer
Sustiva ®
efavirenz
EFV
Bristol-Myers Squibb
(+)-calanolide A
Sarawak Medichem
capravirine
CPV
Pfizer
Bristol-Myers Squibb
Tibotec-Virco Group
Tibotec-Virco Group
Pharmaceutical
Brand Name
Generic Name
Abbreviation
Company
HIV Therapies: Other Classes of Drugs
Viread ™
tenofovir disoproxil
TDF or Bis(POC)
Gilead Sciences
fumarate (DF)
PMPA
Cellular Inhibitors
Droxia ®
hydroxyurea
HU
Bristol-Myers
Squibb
Entry Inhibitors (including Fusion Inhibitors)
Fuzeon ™
enfuvirtide
Trimeris
Trimeris
AnorMED, Inc.
Progenics
Pharmaceuticals
HIV Therapies: Immune-Based Therapies
Brand
Pharmaceutical
Name
Generic Name
Abbreviation
Company
Proleukin ®
aldesleukin, or
IL-2
Chiron Corporation
Interleukin-2
Remune ®
HIV-1
The Immune
Immunogen, or
Response
Salk vaccine
Corporation
HollisEden
Pharmaceuticals
HIV Therapies: Treatments for Side Effects
Brand
Pharmaceutical
Name
Generic Name
Side Effect
Company
Procrit ®
epoetin alfa
Anemia
Ortho Biotech
(erythropoietin)
Serostim ®
somatropin, or
Lipodystrophy
Serono
human growth
Laboratories
hormone
In one embodiment, the compounds of the invention may be employed together with at least one other antiviral agent chosen from reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors and polymerase inhibitors.
In addition, compounds according to the present invention can be administered in combination or alternation with one or more anti-retrovirus, anti-HBV, anti-HCV or anti-herpetic agent or interferon, anti-cancer or antibacterial agents, including but not limited to other compounds of the present invention. Certain compounds according to the present invention may be effective for enhancing the biological activity of certain agents according to the present invention by reducing the metabolism, catabolism or inactivation of other compounds and as such, are co-administered for this intended effect.
VI. Pharmaceutical Compositions
Host, including but not limited to humans, infected with a human immunodeficiency virus, a hepatitis virus, or a gene fragment thereof, can be treated by administering to the patient an effective amount of the active compound or a pharmaceutically acceptable prodrug or salt thereof in the presence of a pharmaceutically acceptable carrier or diluent. The active materials can be administered by any appropriate route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, in liquid or solid form.
A preferred dose of the compound for an HIV or HBV infection will be in the range from about 1 to 50 mg/kg, preferably 1 to 20 mg/kg, of body weight per day, more generally 0.1 to about 100 mg per kilogram body weight of the recipient per day. The effective dosage range of the pharmaceutically acceptable salts and prodrugs can be calculated based on the weight of the parent nucleoside to be delivered. If the salt or prodrug exhibits activity in itself, the effective dosage can be estimated as above using the weight of the salt or prodrug, or by other means known to those skilled in the art.
The compound is conveniently administered in unit any suitable dosage form, including but not limited to but not limited to one containing 7 to 3000 mg, preferably 70 to 1400 mg of active ingredient per unit dosage form. An oral dosage of 50-1000 mg is usually convenient.
Ideally the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 0.2 to 70 μM, preferably about 1.0 to 10 μM. This may be achieved, for example, by the intravenous injection of a 0.1 to 5% solution of the active ingredient, optionally in saline, or administered as a bolus of the active ingredient.
The concentration of active compound in the drug composition will depend on absorption, inactivation and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition. The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.
A preferred mode of administration of the active compound is oral. Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, unit dosage forms can contain various other materials that modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or other enteric agents.
The compound can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like. A syrup may contain, in addition to the active compound(s), sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
The compound or a pharmaceutically acceptable prodrug or salts thereof can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antibiotics, antifungals, anti-inflammatories or other antivirals, including but not limited to other nucleoside compounds. Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as acetates, citrates or phosphates, and agents for the adjustment of tonicity, such as sodium chloride or dextrose. The parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
If administered intravenously, preferred carriers are physiological saline or phosphate buffered saline (PBS).
In a preferred embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including but not limited to implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid. For example, enterically coated compounds can be used to protect cleavage by stomach acid. Methods for preparation of such formulations will be apparent to those skilled in the art. Suitable materials can also be obtained commercially.
Liposomal suspensions (including but not limited to liposomes targeted to infected cells with monoclonal antibodies to viral antigens) are also preferred as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811 (incorporated by reference). For example, liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the active compound or its monophosphate, diphosphate, and/or triphosphate derivatives is then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
VII. Processes for the Preparation of Active Compound
A process for the facile preparation of N4-acyl-cytosine-1,3-dioxolane nucleosides is also provided. The method includes condensation of a 5′-O-silyl protected 5-fluorocytidine-1,3-dioxolane, with either a carboxylic acid chloride, or carboxylic acid anhydride, or a carboxylic acid, followed by desilylation. The other N4-acyl-substituted cytosine nucleosides can be synthesized using the similar approaches.
The N4-acyl-substituted 5-fluorocytidine-1,3-dioxolane disclosed herein can be prepared as described in detail below, or by other assays known to those skilled in the art.
The present invention is further illustrated in the following examples. It will be understood by one of ordinary skill in the art that these examples are in no way limiting and that variations of detail can be made without departing from the spirit and scope of the present invention.
Anhydrous solvents were purchased from Aldrich Chemical Company, Inc. (Milwaukee). Melting points (mp) were determined on an Electrothermal digit melting point apparatus and are uncorrected. 1H and 13C NMR spectra were taken on a Varian Unity Plus 400 spectrometer at room temperature and reported in ppm downfield from internal tetramethylsilane. Deuterium exchange, decoupling experiments or 2D-COSY were performed to confirm proton assignments. Signal multiplicities are represented by s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quadruplet), br (broad), bs (broad singlet), m (multiplet). All J-values are in Hz. Mass spectra were recorded on a JEOL JMS-SX/SX102A/E mass spectrometer. Elemental analyses were performed by Atlantic Microlab Inc. (Norcross, GA). Analytic TLC was performed on Whatman LK6F silica gel plates, and preparative TLC on Whatman PK5F silica gel plates. Column chromatography was carried out on Silica Gel (Fisher, S733-1) at atmospheric pressure.
The 1,3-dioxolane intermediate (i) of the present invention can be synthesized according to U.S. Pat. No. 5,041,449, filed Jun. 29, 1990; U.S. Pat. No. 5,270,315, filed Mar. 7, 1991 (“2-Substituted-4-substituted-1,3-dioxolanes, synthesis and use thereof”); PCT application CA 92/00209, filed May 20, 1992; U.S. Pat. No. 5,756,706, filed May 13, 1994; U.S. Pat. No. 5,744,596, filed Jun. 5, 1995 (“Processes for diastereoselective synthesis of nucleosides”); PCT Application CA 94/00311, filed Jun. 7, 1994; U.S. Pat. No. 5,763,606, filed Feb. 2, 1995 (“Stereoselective synthesis of nucleoside analogues using bicyclic intermediate”); U.S. Patent Application 60/119,756, filed Feb. 11, 1999; U.S. Patent Application 60/119,885, filed Feb. 12, 1999; PCT Application CA 00/00144, filed Feb. 11, 2000; U.S. patent application Ser. No. 09/890,283, filed Feb. 11, 2000 (Stereoselective Synthesis Of Nucleoside Analogues); U.S. Patent Application 60/181,977, filed Feb. 11, 2000; U.S. patent application Ser. No. 09/779,853, filed Feb. 9, 2001; PCT Application CA 01/00117, filed Feb. 2, 2001 (Stereoselective Synthesis Of Nucleoside Analogues); U.S. Patent Application 60/350968, filed Jan. 25, 2002 (Process for producing dioxolane nucleoside analogues) or any manner known to those of ordinary skills in the art.
Additionally, the 1,3-dioxolane intermediate can also be prepared according to the process as set forth in U.S. Pat. No. 5,444,063, filed Oct. 28, 1992; U.S. Pat. No. 5,684,010, filed Jun. 6, 1995; U.S. Pat. No. 5,834,474, filed Apr. 15, 1997; U.S. Pat. No. 5,830,898, filed Apr. 15, 1997; PCT Application WO 94/09793, filed Oct. 28, 1993 (“Enantiomerically β-D-Dioxolane Nucleosides with Selective Anti-Hepatitis B Virus Activity”); U.S. Pat. No. 5,179,104, filed Dec. 5, 1990; PCT Application WO 92/10497, filed Dec. 5, 1990 (“Process for the preparation of enantiomerically pure β-D-(−)-dioxolane”); U.S. Pat. No. 5,767,122, filed Jun. 6, 1995 (“Enantiomerically pure β-D-(−)-dioxolane-nucleosides”); U.S. Pat. No. 5,276,151, filed Dec. 6, 1991 (“Method of Synthesis of 1,3-Dioxolane Nucleosides”); U.S. patent application Ser. No. 09/669,806, filed Sep. 26, 2000 (“Method of Manufacture of 1,3-Oxathiolane Nucleosides”); U.S. Patent Application No. 60/106,664, filed Nov. 2, 1998; U.S. patent application Ser. No. 09/432,247, filed Nov. 2, 1999; and PCT Application WO 00/25797, filed Nov. 2, 1999 (“Combination Therapy to Treat Hepatitis B Virus”); U.S. patent application Ser. No. 10/023,636, filed Dec. 17, 2001; PCT Application US 01/48817, filed Dec. 17, 2001 (“DAPD Combination Therapy with Ribavirin or Mycophenolic Acid”); and U.S. Patent Application No. 60/393,935, filed Jul. 3, 2002 (“Combination Therapy with 1,3, -Dioxolanes and Inosine Monophosphate Dehydrogenase Inhibitors”), all assigned to Emory University, Atlanta, Ga., USA.
The 1,3-dioxolane intermediate (i) is protected at the 5′-hydroxyl with any known method known in the art. The protected 1,3-dioxolane (ii) is then acylated and deprotected to form the N4-acylcytosine-1,3-dixolane nucleoside of formula (iv). See Scheme 1.
##STR00022##
Wherein are R1 is hydrogen or F; P is an oxygen protecting group; and R2 is chosen from alkyl, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, heteroaryl, and C6H4R6 where R6 is chosen from halogen (F, Cl, Br, I), CN, CF3, N3, NO2, alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, and aryl.
To a solution of (ii) and DMAP in anhydrous CH2Cl2 and Et3N at 0° C. was added 4-iodobenzoyl chloride. The reaction mixture was stirred at 0° C. for 30 min, then at room temperature for another 3 h. After removal of the solvent by evaporation, the residue was mixed with THF, and TBAF was added. After stirring for 2 h at room temperature, the solvent was evaporated, and the residue was purified by flash chromatography on silica gel eluting with CH2Cl2/MeOH (96:4) to give, after recrystallization from CH2Cl2/hexane, the title compound vi as a yellow powder.
To a solution of ii and DMAP in anhydrous CH2Cl2 and Et3N at 0 C. was added butyric anhydride. The reaction mixture was stirred at 0° C. for 30 min, then at room temperature for another 2 h. After removal of the solvent by evaporation, the residue was mixed with THF, and TBAF was added. After stirring for 2 h at room temperature, the solvent was evaporated, and the residue was purified by flash chromatography on silica gel eluting with CH2Cl2/MeOH (96:4) to give, after recrystallization from CH2Cl2/hexane, the title compound vii.
To a solution of ii and DMAP in anhydrous CH2Cl2 and Et3N at 0° C. was added 4-fluorobenzoyl chloride. The reaction mixture was stirred at 0° C. for 30 min, then at room temperature for another 2 h. After removal of the solvent by evaporation, the residue was mixed with THF, and TBAF was added. After stirring for 2 h at room temperature, the solvent was evaporated, and the residue was purified by flash chromatography on silica gel eluting with CH2Cl2/MeOH (96:4) to give, after recrystallization from CH2Cl2/hexane, the title compound.
Anti-HIV-1 activity of the compounds was determined in human peripheral blood mononuclear (PBM) cells as described previously (Schinazi R. F., McMillan A., Cannon D., Mathis R., Lloyd R. M. Jr., Peck A., Sommadossi J.-P., St. Clair M., Wilson J., Furman P. A., Painter G., Choi W.-B., Liotta D.C. Antimicrob. Agents Chemother. 1992, 36, 2423; Schinazi R. F., Sommadossi J.-P., Saalmann V., Cannon D., Xie M.-Y., Hart G., Smith G., Hahn E. Antimicrob. Agents Chemother. 1990, 34, 1061). Stock solutions (20-40 mM) of the compounds were prepared in sterile DMSO and then diluted to the desired concentration in growth medium. Cells were infected with the prototype HIV-1LAI at a multiplicity of infection of 0.01. Virus obtained from the cell supernatant was quantified on day 6 after infection by a reverse transcriptase assay using (rA)n-(dT)12-18 as template-primer. The DMSO present in the diluted solution (<0.1%) had no effect on the virus yield. AZT was included as positive control. The antiviral EC50 and EC90 were obtained from the concentration-response curve using the median effective method described previously (Chou T.-C. & Talalay P. Adv. Enzyme Regul. 1984, 22, 27-55; Belen'kii M. S. & Schinazi R. F. Antiviral Res. 1994, 25, 1-11).
In a second antiviral testing system, the potency of the compounds was determined by measurement of viral RNA accumulation in HIV-IRF infected MT-2 cells (Bacheler L T, Paul M, Otto M J, Jadhav P K, Stone B A & Miller J A (1994) An assay for HIV RNIn infected cell lysates, and its use for rapid evaluation of antiviral efficacy. Antivir. Chem. Chemother. 5:111-121). The virus titer was established to determine the dilution producing 15 to 30 ng/RNA per well of HIV RNIn 3 days of infection. HIV-1 RNA was quantified using biotinylated capture and alkaline phosphatase-derivatized reporter oligonucleotides as described previously (Charvet A-S, Camplo M, Faury P, Graciet J C, Mourier N, Chermann J C & Kraus J L (1994) Inhibition of human immunodeficiency virus type 1 replication by phosphonoformate- and phosphonoacetate-2′,3′-dideoxy-3′-thiacytidine conjugates. J. Med. Chem. 37:2216-2223). In a third system, the effect of analogs on the replication of HIV-INL4-3 was determined via the InterCompany Consortium consensus p24 assay as previously described (Jadhav P K & MacKay M F (1997) Cyclic urea amide: HIV-1 protease inhibitors with low nanomolar potency against both wild types and protease inhibitor resistant mutants of HIV. J. Med. Chem. 40:181-190). Recombinant viruses were recovered by transfecting the appropriate NL4-3 plasmid by lipofection. Virus stocks recovered 7 to 10 days post-transfection were titered on MT-4 cells to determine if the dilution produced 1,000 to 3,000 ng p24 in 4 days. This dilution was then used in drug susceptibility assays, where drug was added 24 h post infection of cells, and p24 quantified by ELISA 3 days later.
The anti-HBV activity of the compounds was determined by treating the AD-38 cell line carrying wild type HBV under the control of tetracycline (Ladner S. K., Otto M. J., Barker C. S., Zaifert K., Wang G. H., Guo J. T., Seeger C. & King R. W. Antimicrob. Agents Chemother. 1997, 41, 1715-1720). Removal of tetracycline from the medium [Tet(−)] results in the production of HBV. The levels of HBV in the culture supernatant fluids from cells treated with the compounds were compared with that of the untreated controls. Control cultures with tetracycline [Tet(+)] were also maintained to determine the basal levels of HBV expression. 3TC was included as positive control.
The toxicity of the compounds was assessed in Vero, human PBM, CEM (human lymphoblastoid), MT-2, and HepG2 cells, as described previously (Schinazi R. F., Sommadossi J.-P., Saalmann V., Cannon D. L., Xie M.-Y., Hart G. C., Smith G. A. & Hahn E. F. Antimicrob Agents Chemother. 1990, 34, 1061-1067). Cycloheximide was included as positive cytotoxic control, and untreated cells exposed to solvent were included as negative controls. The cytotoxicity IC50 was obtained from the concentration-response curve using the median effective method described previously (Chou T.-C. & Talalay P. Adv. Enzyme Regul. 1984, 22, 27-55; Belen'kii M. S. & Schinazi R. F. Antiviral Res. 1994, 25, 1-11).
Watanabe, Kyoichi A., Shi, Junxing, Otto, Michael J.
| Patent | Priority | Assignee | Title |
| 10000523, | Mar 06 2015 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment |
| 10005811, | Mar 06 2015 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment |
| 10239911, | Mar 06 2015 | Atea Pharmaceuticals, Inc. | Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment |
| 10287311, | May 30 2003 | GILEAD SCIENCES, INC | Modified fluorinated nucleoside analogues |
| 10519186, | Feb 01 2017 | ATEA PHARMACEUTICALS, INC | Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus |
| 10815266, | Mar 06 2015 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment |
| 10870672, | Mar 06 2015 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment |
| 10870673, | Mar 06 2015 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment |
| 10874687, | Feb 27 2020 | ATEA PHARMACEUTICALS, INC | Highly active compounds against COVID-19 |
| 10875885, | Mar 06 2015 | Atea Pharmaceuticals, Inc. | β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n6-substituted purine nucleotides for HCV treatment |
| 10894804, | Feb 01 2017 | Atea Pharmaceuticals, Inc. | Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus |
| 10906928, | Feb 01 2017 | Atea Pharmaceuticals, Inc. | Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus |
| 10946033, | Sep 07 2016 | Atea Pharmaceuticals, Inc. | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment |
| 11690860, | Apr 10 2018 | Atea Pharmaceuticals, Inc. | Treatment of HCV infected patients with cirrhosis |
| 11707480, | Feb 27 2020 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| 11738038, | Feb 27 2020 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| 11813278, | Feb 27 2020 | ATEA PHARMACEUTICALS, INC | Highly active compounds against COVID-19 |
| 9828410, | Mar 06 2015 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment |
| Patent | Priority | Assignee | Title |
| 4522811, | Jul 08 1982 | SYNTEX U S A INC | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| 4957924, | Aug 15 1987 | Burroughs Wellcome Co.; BURROUGHS WELLCOME CO | Therapeutic valine esters of acyclovir and pharmaceutically acceptable salts thereof |
| 5561120, | May 25 1993 | Yale University | Method for treating HBV infections with L-2',3'-didehydro-dideoxy-5-fluorocytidine |
| 5703058, | Jan 27 1995 | Emory University | Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent |
| 5905070, | Jan 27 1995 | Emory University | [5--Caboxamido or 5--fluoro]--[2', 3'--unsaturated or 3'--modified]--pyrimidine nucleosides |
| 5922867, | Dec 14 1995 | Biochem Pharma Inc. | Method and compositions for the synthesis of dioxolane nucleosides with β configuration |
| 6232300, | Jan 27 1995 | Emory University | Treatment of HIV by administration of β-D-2', 3'-didehydro-2',3'-dideoxy-5-fluorocytidine (D4FC) |
| 6350753, | Apr 11 1988 | BIOCHEM PHARMA INC | 2-Substituted-4-substituted-1,3-dioxolanes and use thereof |
| 20030013660, | |||
| EP409227, | |||
| EP99493, | |||
| NL8901258, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Jun 21 2007 | Pharmasset, Inc. | (assignment on the face of the patent) | / | |||
| Feb 10 2012 | PHARMASSET, INC | Gilead Pharmasset LLC | CHANGE OF NAME SEE DOCUMENT FOR DETAILS | 028081 | /0686 |
| Date | Maintenance Fee Events |
| Oct 04 2012 | M2552: Payment of Maintenance Fee, 8th Yr, Small Entity. |
| Mar 12 2013 | ASPN: Payor Number Assigned. |
| Mar 26 2013 | STOL: Pat Hldr no Longer Claims Small Ent Stat |
| Jan 27 2017 | REM: Maintenance Fee Reminder Mailed. |
| Jun 21 2017 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| Dec 28 2013 | 4 years fee payment window open |
| Jun 28 2014 | 6 months grace period start (w surcharge) |
| Dec 28 2014 | patent expiry (for year 4) |
| Dec 28 2016 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Dec 28 2017 | 8 years fee payment window open |
| Jun 28 2018 | 6 months grace period start (w surcharge) |
| Dec 28 2018 | patent expiry (for year 8) |
| Dec 28 2020 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Dec 28 2021 | 12 years fee payment window open |
| Jun 28 2022 | 6 months grace period start (w surcharge) |
| Dec 28 2022 | patent expiry (for year 12) |
| Dec 28 2024 | 2 years to revive unintentionally abandoned end. (for year 12) |